LI_DRUG_NAME,BRAND_NAME,LI_FORM,PBS_CODE,BENEFIT_TYPE_CODE,MAXIMUM_QUANTITY,NUMBER_OF_REPEATS,PACK_SIZE,STREAMLINE,LI_HTML_TEXT,CONDITION_TYPE_CODE,CONDITION,BENEFIT_TYPE,DOSE,ind,reind,grand,PHASE
Tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,9659J,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,400 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,9659J,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,400 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,9659J,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 5 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,400 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,9659J,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,400 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,9659J,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,400 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,9659J,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,400 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,9671B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,80 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,9671B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,80 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,9671B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 5 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,80 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,9671B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,80 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,9671B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,80 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,9671B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,80 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,11743C,A,1,5,4,NA,"<p>Active giant cell arteritis</p>
<p>Initial treatment</p>
<p>Must be treated by a rheumatologist, clinical immunologist or neurologist experienced in the management of giant cell arteritis; AND</p>
 <p>Patient must have clinical symptoms of active giant cell arteritis in the absence of any other identifiable cause; AND</p>
 <p>Patient must have an ESR equal to or greater than 30 mm/hour within the past 6 weeks; or</p>
 <p>Patient must have a CRP equal to or greater than 10 mg/L within the past 6 weeks; or</p>
 <p>Patient must have active giant cell arteritis confirmed by positive temporal artery biopsy or imaging; AND</p>
 <p>Patient must have had a history of an ESR equal to or greater than 50 mm/hour or a CRP equal to or greater than 24.5 mg/L at diagnosis; AND</p>
 <p>Patient must have had temporal artery biopsy revealing features of giant cell arteritis at diagnosis; or</p>
 <p>Patient must have had evidence of large-vessel vasculitis by magnetic resonance (MR) or computed tomography (CT) angiography or PET/CT at diagnosis; AND</p>
 <p>The treatment must be in combination with a tapering course of corticosteroids; AND</p>
 <p>The treatment must not exceed 52 weeks in total including initial and continuing applications; AND</p>
 <p>Patient must be aged 50 years or older.</p>

 <p align=\""justify\"">Clinical symptoms of giant cell arteritis at diagnosis include unequivocal cranial symptoms of giant cell arteritis (new onset localized headache, scalp tenderness, temporal artery tenderness or decreased pulsation, ischemia related vision loss, or otherwise unexplained mouth or jaw pain upon mastication); or symptoms of polymyalgia rheumatica, defined as shoulder and/or hip girdle pain associated with inflammatory morning stiffness.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form;</p><p align=\""justify\"">(2) a completed Giant Cell Arteritis - Supporting Information Form; and</p><p align=\""justify\"">(3) documentation that the patient has active giant cell arteritis including pathology reports outlining the patient&apos;s ESR or CRP levels within the last 6 weeks, or positive temporal artery biopsy or imaging;</p><p align=\""justify\"">(4) documentation that the patient has been diagnosed with giant cell arteritis with a history of an ESR equal to or greater than 50 mm/hour or a CRP equal to or greater than 24.5 mg/L at diagnosis.</p>",giant cell arteritis,GCA,Authority,162 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,11721X,A,1,6,4,NA,"<p>Active giant cell arteritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist, clinical immunologist or neurologist experienced in the management of giant cell arteritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>The treatment must not exceed 52 weeks in total including initial and continuing applications.</p>",giant cell arteritis,GCA,Authority,162 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,9672C,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,9672C,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,9672C,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 5 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,9672C,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,9672C,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,9672C,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Tofacitinib,Xeljanz,Tablet 5 mg,11675L,A,1,5,56,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",psoriatic arthritis,PsA,Authority,5 ,FALSE,FALSE,FALSE,Continuing
Tofacitinib,Xeljanz,Tablet 5 mg,11675L,A,1,5,56,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,5 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,11744D,A,1,5,4,NA,"<p>Active giant cell arteritis</p>
<p>Initial treatment</p>
<p>Must be treated by a rheumatologist, clinical immunologist or neurologist experienced in the management of giant cell arteritis; AND</p>
 <p>Patient must have clinical symptoms of active giant cell arteritis in the absence of any other identifiable cause; AND</p>
 <p>Patient must have an ESR equal to or greater than 30 mm/hour within the past 6 weeks; or</p>
 <p>Patient must have a CRP equal to or greater than 10 mg/L within the past 6 weeks; or</p>
 <p>Patient must have active giant cell arteritis confirmed by positive temporal artery biopsy or imaging; AND</p>
 <p>Patient must have had a history of an ESR equal to or greater than 50 mm/hour or a CRP equal to or greater than 24.5 mg/L at diagnosis; AND</p>
 <p>Patient must have had temporal artery biopsy revealing features of giant cell arteritis at diagnosis; or</p>
 <p>Patient must have had evidence of large-vessel vasculitis by magnetic resonance (MR) or computed tomography (CT) angiography or PET/CT at diagnosis; AND</p>
 <p>The treatment must be in combination with a tapering course of corticosteroids; AND</p>
 <p>The treatment must not exceed 52 weeks in total including initial and continuing applications; AND</p>
 <p>Patient must be aged 50 years or older.</p>

 <p align=\""justify\"">Clinical symptoms of giant cell arteritis at diagnosis include unequivocal cranial symptoms of giant cell arteritis (new onset localized headache, scalp tenderness, temporal artery tenderness or decreased pulsation, ischemia related vision loss, or otherwise unexplained mouth or jaw pain upon mastication); or symptoms of polymyalgia rheumatica, defined as shoulder and/or hip girdle pain associated with inflammatory morning stiffness.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form;</p><p align=\""justify\"">(2) a completed Giant Cell Arteritis - Supporting Information Form; and</p><p align=\""justify\"">(3) documentation that the patient has active giant cell arteritis including pathology reports outlining the patient&apos;s ESR or CRP levels within the last 6 weeks, or positive temporal artery biopsy or imaging;</p><p align=\""justify\"">(4) documentation that the patient has been diagnosed with giant cell arteritis with a history of an ESR equal to or greater than 50 mm/hour or a CRP equal to or greater than 24.5 mg/L at diagnosis.</p>",giant cell arteritis,GCA,Authority,162 ,FALSE,FALSE,FALSE,Initial
Tofacitinib,Xeljanz,Tablet 5 mg,10517M,A,1,3,56,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,5 ,FALSE,FALSE,FALSE,Initial
Tofacitinib,Xeljanz,Tablet 5 mg,10517M,A,1,3,56,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,5 ,FALSE,FALSE,FALSE,Initial
Tofacitinib,Xeljanz,Tablet 5 mg,10517M,A,1,3,56,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,5 ,FALSE,FALSE,FALSE,Initial
Tofacitinib,Xeljanz,Tablet 5 mg,10517M,A,1,3,56,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,5 ,FALSE,FALSE,FALSE,Initial
Tofacitinib,Xeljanz,Tablet 5 mg,11690G,A,1,3,56,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,5 ,FALSE,FALSE,FALSE,Initial
Tofacitinib,Xeljanz,Tablet 5 mg,11690G,A,1,3,56,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,5 ,FALSE,FALSE,FALSE,Initial
Tofacitinib,Xeljanz,Tablet 5 mg,11690G,A,1,3,56,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,5 ,FALSE,FALSE,FALSE,Initial
Tofacitinib,Xeljanz,Tablet 5 mg,11690G,A,1,3,56,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,5 ,FALSE,FALSE,FALSE,Initial
Tofacitinib,Xeljanz,Tablet 5 mg,10511F,A,1,5,56,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,5 ,FALSE,FALSE,FALSE,Continuing
Tofacitinib,Xeljanz,Tablet 5 mg,10511F,A,1,5,56,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,5 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,11722Y,A,1,6,4,NA,"<p>Active giant cell arteritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist, clinical immunologist or neurologist experienced in the management of giant cell arteritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>The treatment must not exceed 52 weeks in total including initial and continuing applications.</p>",giant cell arteritis,GCA,Authority,162 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,10954M,A,1,5,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,162 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,10954M,A,1,5,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,162 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,9658H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,9658H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,9658H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 5 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,9658H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,9658H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 200 mg in 10 mL,9658H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,9657G,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,80 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,9657G,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,80 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,9657G,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 5 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,80 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,9657G,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,80 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,9657G,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,80 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 80 mg in 4 mL,9657G,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,80 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,9673D,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,400 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,9673D,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,400 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,9673D,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 5 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,400 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,9673D,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate number of vials of appropriate strength to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 8 mg per kg. A separate authority prescription form must be completed for each strength requested.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,400 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,9673D,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,400 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra,Concentrate for injection 400 mg in 20 mL,9673D,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,400 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,11565Q,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,162 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,11565Q,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,162 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,11565Q,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,162 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,11565Q,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,162 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,10951J,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,162 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,10951J,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,162 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,10951J,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,162 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra Subcutaneous Injection,Injection 162 mg in 0.9 mL single use pre-filled syringe,10951J,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,162 ,FALSE,FALSE,FALSE,Initial
Tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,11567T,A,1,5,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,162 ,FALSE,FALSE,FALSE,Continuing
Tocilizumab,Actemra ACTPen,Injection 162 mg in 0.9 mL single use pre-filled pen,11567T,A,1,5,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,162 ,FALSE,FALSE,FALSE,Continuing
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10894J,A,4,0,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10894J,A,4,0,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10894J,A,4,0,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,12307R,A,1,5,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug for this condition; AND</p>
 <p>The treatment must not exceed a maximum of 24 weeks with this drug per authorised course under this restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">An adequate response to therapy with this biological medicine is defined as a reduction from baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score by 2 or more units (on a scale of 0-10) and 1 of the following:</p><p align=\""justify\"">(a) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(b) a CRP measurement reduced by at least 20% from baseline.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated CRP level could not be met under an initial treatment restriction, a reduction in the BASDAI score from baseline will suffice for the purposes of administering this continuing treatment restriction.</p>
 <p align=\""justify\"">The patient remains eligible to receive continuing treatment with the same biological medicine in courses of up to 24 weeks providing they continue to sustain an adequate response. It is recommended that a patient be reviewed in the month prior to completing their current course of treatment.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,150 ,FALSE,FALSE,FALSE,Continuing
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,12307R,A,1,5,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Grandfather treatment</p>
<p>Patient must have previously received non-PBS-subsidised treatment with this drug for this indication prior to 1 April 2021; AND</p>
 <p>Patient must have had chronic lower back pain and stiffness for 3 or more months that was relieved by exercise but not rest, prior to initiating non-PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must have had failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months, prior to initiating non-PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must have had one or more of the following: (a) enthesitis (heel); (b) uveitis; (c) dactylitis; (d) psoriasis; (e) inflammatory bowel disease; or (f) positive for Human Leukocyte Antigen B27 (HLA-B27); prior to initiating non-PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>The condition must not be radiographically evidenced on plain x-ray of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis prior to commencing non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The condition must have been diagnosed as non-radiographic axial spondyloarthritis, as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria, prior to having commenced non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The condition must have been sacroiliitis with active inflammation and/or oedema on non-contrast Magnetic Resonance Imaging (MRI) prior to commencing non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The condition must have had presence of Bone Marrow Oedema (BMO) depicted as a hyperintense signal on a Short Tau Inversion Recovery (STIR) image (or equivalent) prior to commencing non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The condition must have had BMO depicted as a hypointense signal on a T1 weighted image (without gadolinium) prior to commencing non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The treatment must not exceed a maximum of 24 weeks with this drug under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""left\"">The following criteria indicate failure to achieve an adequate response to NSAIDs and must have been demonstrated prior to initiation of non-PBS subsidised treatment with this biological medicine for this condition:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) C-reactive protein (CRP) level greater than 10 mg per L.</p>
 <p align=\""left\"">The BASDAI score and CRP level must have been determined at the completion of the 3-month NSAID and exercise trial, but prior to ceasing NSAID treatment. All measures must have been no more than 1 month old at the time of initiating non-PBS subsidised treatment with this biological medicine for this condition.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">A Grandfathered patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the continuing treatment criteria.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">The baseline BASDAI score and CRP level must also be documented in the patient&apos;s medical records.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,150 ,FALSE,FALSE,TRUE,Grandfathered
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10898N,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,12321L,A,5,0,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 1 (New patient)</p>
<p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had chronic lower back pain and stiffness for 3 or more months that is relieved by exercise but not rest; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must have one or more of the following: (a) enthesitis (heel); (b) uveitis; (c) dactylitis; (d) psoriasis; (e) inflammatory bowel disease; or (f) positive for Human Leukocyte Antigen B27 (HLA-B27); AND</p>
 <p>The condition must not be radiographically evidenced on plain x-ray of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis; AND</p>
 <p>The condition must be non-radiographic axial spondyloarthritis, as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria; AND</p>
 <p>The condition must be sacroiliitis with active inflammation and/or oedema on non-contrast Magnetic Resonance Imaging (MRI); AND</p>
 <p>The condition must have presence of Bone Marrow Oedema (BMO) depicted as a hyperintense signal on a Short Tau Inversion Recovery (STIR) image (or equivalent); AND</p>
 <p>The condition must have BMO depicted as a hypointense signal on a T1 weighted image (without gadolinium); AND</p>
 <p>Patient must not receive more than 20 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">The stated maximum quantity of 5 with zero repeats is intended for a patient undergoing the loading dose regimen of 150 mg administered at weeks 0, 1, 2, 3, and 4 (a total of 5 doses) followed by monthly administration thereafter.</p><p align=\""justify\"">State in the application whether a loading dose regimen is intended or not.</p><p align=\""justify\"">Where a loading dose regimen is intended, request a maximum quantity of 5 and zero repeats to cover doses at weeks 0, 1, 2, 3 and 4. Doses at week 8, 12, and 16 can be sought under the relevant &apos;Balance of supply&apos; listing.</p><p align=\""justify\"">Where no loading dose regimen is intended, request a maximum quantity of 1 and seek an increase in the number of repeats from zero to 4 repeats to cover dosing at weeks 4, 8, 12 and 16. Where increased repeats are sought, the maximum quantity sought must not be greater than 1.</p>
 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response to NSAIDs and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""left\"">The baseline BASDAI score and CRP level must be determined at the completion of the 3-month NSAID and exercise trial, but prior to ceasing NSAID treatment. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">The baseline BASDAI score and CRP level must also be documented in the patient&apos;s medical records.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,12321L,A,5,0,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had chronic lower back pain and stiffness for 3 or more months that is relieved by exercise but not rest; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must have one or more of the following: (a) enthesitis (heel); (b) uveitis; (c) dactylitis; (d) psoriasis; (e) inflammatory bowel disease; or (f) positive for Human Leukocyte Antigen B27 (HLA-B27); AND</p>
 <p>The condition must not be radiographically evidenced on plain x-ray of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis; AND</p>
 <p>The condition must be non-radiographic axial spondyloarthritis, as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria; AND</p>
 <p>The condition must be sacroiliitis with active inflammation and/or oedema on non-contrast Magnetic Resonance Imaging (MRI); AND</p>
 <p>The condition must have presence of Bone Marrow Oedema (BMO) depicted as a hyperintense signal on a Short Tau Inversion Recovery (STIR) image (or equivalent); AND</p>
 <p>The condition must have BMO depicted as a hypointense signal on a T1 weighted image (without gadolinium); AND</p>
 <p>Patient must not receive more than 20 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">The following must be provided at the time of application and documented in the patient&apos;s medical records:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) C-reactive protein (CRP) level greater than 10 mg per L.</p>
 <p align=\""justify\"">The BASDAI score and CRP level must be no more than 4 weeks old at the time of this application.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">The stated maximum quantity of 5 with zero repeats is intended for a patient undergoing the loading dose regimen of 150 mg administered at weeks 0, 1, 2, 3, and 4 (a total of 5 doses) followed by monthly administration thereafter.</p><p align=\""justify\"">State in the application whether a loading dose regimen is intended or not.</p><p align=\""justify\"">Where a loading dose regimen is intended, request a maximum quantity of 5 and zero repeats to cover doses at weeks 0, 1, 2, 3 and 4. Doses at week 8, 12, and 16 can be sought under the relevant &apos;Balance of supply&apos; listing.</p><p align=\""justify\"">Where no loading dose regimen is intended, request a maximum quantity of 1 and seek an increase in the number of repeats from zero to 4 repeats to cover dosing at weeks 4, 8, 12 and 16. Where increased repeats are sought, the maximum quantity sought must not be greater than 1.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,12321L,A,5,0,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with biological medicines more than three times for this PBS-indication during the current treatment cycle; AND</p>
 <p>Patient must not have failed PBS-subsidised therapy with this biological medicine for this PBS indication more than once in the current treatment cycle; AND</p>
 <p>Patient must not receive more than 20 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">An application for Initial 2 treatment must indicate whether the patient has demonstrated an adequate response (an absence of treatment failure), failed or experienced an intolerance to the most recent supply of biological medicine treatment.</p><p align=\""justify\"">A new baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and C-reactive protein (CRP) level may be provided at the time of this application.</p>
 <p align=\""justify\"">An adequate response to therapy with this biological medicine is defined as a reduction from baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score by 2 or more units (on a scale of 0-10) and 1 of the following:</p><p align=\""justify\"">(a) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(b) a CRP measurement reduced by at least 20% from baseline.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the most recent supply of biological medicine must be conducted following a minimum of 12 weeks of treatment.</p>
 <p align=\""justify\"">BASDAI scores and CRP levels must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">The following must be provided at the time of application and documented in the patient&apos;s medical records:</p><p align=\""justify\"">(a) the BASDAI score; and</p><p align=\""justify\"">(b) the C-reactive protein (CRP) level.</p>
 <p align=\""justify\"">The stated maximum quantity of 5 with zero repeats is intended for a patient undergoing the loading dose regimen of 150 mg administered at weeks 0, 1, 2, 3, and 4 (a total of 5 doses) followed by monthly administration thereafter.</p><p align=\""justify\"">State in the application whether a loading dose regimen is intended or not.</p><p align=\""justify\"">Where a loading dose regimen is intended, request a maximum quantity of 5 and zero repeats to cover doses at weeks 0, 1, 2, 3 and 4. Doses at week 8, 12, and 16 can be sought under the relevant &apos;Balance of supply&apos; listing.</p><p align=\""justify\"">Where no loading dose regimen is intended, request a maximum quantity of 1 and seek an increase in the number of repeats from zero to 4 repeats to cover dosing at weeks 4, 8, 12 and 16. Where increased repeats are sought, the maximum quantity sought must not be greater than 1.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,12297F,A,1,0,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial 1 (New patient), Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patients) restriction to complete 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 20 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 20 weeks treatment; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,12297F,A,1,0,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Continuing treatment or Grandfather patient - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Grandfathered treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the continuing treatment restriction or the grandfather restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,150 ,FALSE,FALSE,TRUE,Grandfathered
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10901R,A,1,2,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10906B,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,150 ,FALSE,FALSE,FALSE,Continuing
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10906B,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,150 ,FALSE,FALSE,FALSE,Continuing
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10895K,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,150 ,FALSE,FALSE,FALSE,Continuing
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10895K,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,150 ,FALSE,FALSE,FALSE,Continuing
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10890E,A,4,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10890E,A,4,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10890E,A,4,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10900Q,A,4,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10900Q,A,4,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10900Q,A,4,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,150 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10893H,A,1,2,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,150 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,9035M,A,2,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,9035M,A,2,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,9035M,A,2,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,9035M,A,2,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10899P,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,150 ,FALSE,FALSE,FALSE,Continuing
Secukinumab,Cosentyx,Injection 150 mg in 1 mL pre-filled pen,10899P,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,150 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9085E,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9085E,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9085E,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9085E,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",11201M,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",11201M,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">Each application for subsequent continuing treatment with this drug must include an assessment of the patient&apos;s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,9035M,A,2,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,9035M,A,2,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,9035M,A,2,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,9035M,A,2,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Meloxicam,Mobic,Tablet 15 mg,8562P,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9456Q,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9456Q,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Pharmacor Meloxicam 15,Tablet 15 mg,8562P,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9090K,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9090K,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Meloxiauro 15,Tablet 15 mg,8562P,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9459W,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9459W,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9459W,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9459W,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Meloxicam,Movalis 15,Tablet 15 mg,8562P,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8637N,A,2,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8637N,A,2,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8637N,A,2,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8637N,A,2,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Meloxicam,APO-Meloxicam,Tablet 15 mg,8562P,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Meloxibell,Tablet 7.5 mg,8561N,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11219L,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11219L,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,CIPLA MELOXICAM 15,Tablet 15 mg,8562P,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Moxicam,Capsule 7.5 mg,8887R,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,11207W,A,2,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under the first continuing treatment restriction, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,11207W,A,2,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,MELOBIC,Capsule 7.5 mg,8887R,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Meloxicam Sandoz,Tablet 7.5 mg,8561N,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,APX-Meloxicam,Tablet 15 mg,8562P,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,11207W,A,2,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under the first continuing treatment restriction, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,11207W,A,2,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Meloxicam-GA,Tablet 15 mg,8562P,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9089J,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9089J,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9089J,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9089J,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Meloxicam,Meloxibell,Tablet 15 mg,8562P,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11217J,S,1,5,1,9481,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,50 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Meloxicam Sandoz,Capsule 7.5 mg,8887R,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,APX-Meloxicam,Tablet 7.5 mg,8561N,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Movalis 15,Capsule 15 mg,8888T,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11208X,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under the first continuing treatment restriction, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11208X,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Meloxicam-GA,Tablet 7.5 mg,8561N,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,11197H,A,2,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,11197H,A,2,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Moxicam 7.5,Tablet 7.5 mg,8561N,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,11197H,A,2,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,11197H,A,2,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Chem mart Meloxicam,Capsule 15 mg,8888T,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9085E,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9085E,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9085E,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9085E,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Baricitinib,Olumiant,Tablet 4 mg,11447L,A,1,3,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,4 ,FALSE,FALSE,FALSE,Initial
Baricitinib,Olumiant,Tablet 4 mg,11447L,A,1,3,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,4 ,FALSE,FALSE,FALSE,Initial
Baricitinib,Olumiant,Tablet 4 mg,11447L,A,1,3,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,4 ,FALSE,FALSE,FALSE,Initial
Baricitinib,Olumiant,Tablet 4 mg,11447L,A,1,3,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,4 ,FALSE,FALSE,FALSE,Initial
Meloxicam,Chem mart Meloxicam,Capsule 7.5 mg,8887R,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9457R,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9457R,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9457R,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9457R,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Baricitinib,Olumiant,Tablet 4 mg,11443G,A,1,5,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,4 ,FALSE,FALSE,FALSE,Continuing
Baricitinib,Olumiant,Tablet 4 mg,11443G,A,1,5,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,4 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Terry White Chemists Meloxicam,Capsule 15 mg,8888T,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Baricitinib,Olumiant,Tablet 2 mg,11437Y,A,1,3,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,2 ,FALSE,FALSE,FALSE,Initial
Baricitinib,Olumiant,Tablet 2 mg,11437Y,A,1,3,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,2 ,FALSE,FALSE,FALSE,Initial
Baricitinib,Olumiant,Tablet 2 mg,11437Y,A,1,3,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,2 ,FALSE,FALSE,FALSE,Initial
Baricitinib,Olumiant,Tablet 2 mg,11437Y,A,1,3,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,2 ,FALSE,FALSE,FALSE,Initial
Meloxicam,Pharmacor Meloxicam 7.5,Tablet 7.5 mg,8561N,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",11220M,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",11220M,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Baricitinib,Olumiant,Tablet 2 mg,11442F,A,1,5,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,2 ,FALSE,FALSE,FALSE,Continuing
Baricitinib,Olumiant,Tablet 2 mg,11442F,A,1,5,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,2 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Meloxicam AN,Tablet 15 mg,8562P,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Movalis 7.5,Tablet 7.5 mg,8561N,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9086F,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9086F,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,MELOBIC,Tablet 7.5 mg,8561N,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Meloxicam AN,Tablet 7.5 mg,8561N,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",11218K,S,1,5,1,7276,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological disease modifying anti-rheumatic drug (bDMARD) treatment for this condition; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction.</p>

 <p/><p align=\""justify\"">For the purposes of this restriction bDMARD means abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab or tofacitinib.</p><p/>
 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.<br/><br/></p><p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,50 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Meloxiauro 7.5,Tablet 7.5 mg,8561N,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9089J,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9089J,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9089J,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9089J,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Meloxicam,Mobic,Tablet 7.5 mg,8561N,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9086F,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9086F,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Mobic,Capsule 15 mg,8888T,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,CIPLA MELOXICAM 7.5,Tablet 7.5 mg,8561N,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",11201M,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",11201M,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">Each application for subsequent continuing treatment with this drug must include an assessment of the patient&apos;s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,APO-Meloxicam,Capsule 15 mg,8888T,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,MELOBIC,Capsule 15 mg,8888T,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9460X,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9460X,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Moxicam,Capsule 15 mg,8888T,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",11202N,S,1,5,1,9156,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,50 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Meloxicam Sandoz,Capsule 15 mg,8888T,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,APO-Meloxicam,Tablet 7.5 mg,8561N,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9459W,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9459W,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9459W,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9459W,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Meloxicam,MELOBIC,Tablet 15 mg,8562P,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9090K,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9090K,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Terry White Chemists Meloxicam,Capsule 7.5 mg,8887R,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Moxicam 15,Tablet 15 mg,8562P,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9087G,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9087G,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9087G,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9087G,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Meloxicam,Meloxicam Sandoz,Tablet 15 mg,8562P,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,15 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11196G,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11196G,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">Each application for subsequent continuing treatment with this drug must include an assessment of the patient&apos;s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,APO-Meloxicam,Capsule 7.5 mg,8887R,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Mobic,Capsule 7.5 mg,8887R,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,9036N,A,2,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,9036N,A,2,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Meloxicam,Movalis 7.5,Capsule 7.5 mg,8887R,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,5 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9455P,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9455P,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9455P,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9455P,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,11204Q,A,2,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,11204Q,A,2,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">Each application for subsequent continuing treatment with this drug must include an assessment of the patient&apos;s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9456Q,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9456Q,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11208X,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under the first continuing treatment restriction, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11208X,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",11198J,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under the first continuing treatment restriction, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",11198J,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9460X,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9460X,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8778B,A,2,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8778B,A,2,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8778B,A,2,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8778B,A,2,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8778B,A,2,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8778B,A,2,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8778B,A,2,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8778B,A,2,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9458T,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9458T,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8779C,A,2,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8779C,A,2,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11196G,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11196G,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">Each application for subsequent continuing treatment with this drug must include an assessment of the patient&apos;s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8637N,A,2,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8637N,A,2,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8637N,A,2,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8637N,A,2,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8779C,A,2,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8779C,A,2,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9088H,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9088H,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9087G,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9087G,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9087G,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9087G,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11211C,S,1,5,1,7276,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological disease modifying anti-rheumatic drug (bDMARD) treatment for this condition; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction.</p>

 <p/><p align=\""justify\"">For the purposes of this restriction bDMARD means abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab or tofacitinib.</p><p/>
 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.<br/><br/></p><p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9455P,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9455P,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9455P,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9455P,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8638P,A,2,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8638P,A,2,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8638P,A,2,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,8638P,A,2,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",11198J,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under the first continuing treatment restriction, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",11198J,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,11204Q,A,2,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,11204Q,A,2,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">Each application for subsequent continuing treatment with this drug must include an assessment of the patient&apos;s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11219L,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11219L,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",11215G,S,1,5,1,9481,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9458T,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injection 50 mg in 1 mL single use auto-injector, 4",9458T,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",11216H,S,1,5,1,9156,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9088H,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Brenzys,"Injections 50 mg in 1 mL single use pre-filled syringes, 4",9088H,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,9036N,A,2,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,Injection set containing 4 vials powder for injection 25 mg and 4 pre-filled syringes solvent 1 mL,9036N,A,2,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,25 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",11220M,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",11220M,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9457R,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9457R,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9457R,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Etanercept,Enbrel,"Injection 50 mg in 1 mL single use auto-injector, 4",9457R,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Methotrexate,Trexject,Injection 20 mg in 0.4 mL pre-filled syringe,11288D,S,4,5,1,7488,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must be unsuitable for administration of an oral form of methotrexate for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Methotrexate,Methoblastin PFS,Injection 10 mg in 0.4 mL pre-filled syringe,11526P,S,1,5,4,7488,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must be unsuitable for administration of an oral form of methotrexate for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Methotrexate,Trexject,Injection 25 mg in 0.5 mL pre-filled syringe,11295L,S,4,5,1,7488,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must be unsuitable for administration of an oral form of methotrexate for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,25 ,FALSE,FALSE,FALSE,Continuing
Methotrexate,Trexject,Injection 15 mg in 0.3 mL pre-filled syringe,11268C,S,4,5,1,7488,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must be unsuitable for administration of an oral form of methotrexate for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,15 ,FALSE,FALSE,FALSE,Continuing
Methotrexate,Methoblastin PFS,Injection 25 mg in 1 mL pre-filled syringe,11544N,S,1,5,4,7488,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must be unsuitable for administration of an oral form of methotrexate for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,25 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,12328W,S,1,5,2,11634,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 units (on a scale of 0-10) in the BASDAI score combined with at least 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celaxib,Capsule 200 mg,8440F,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,200 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,APO-Celecoxib,Capsule 200 mg,8440F,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,200 ,FALSE,FALSE,FALSE,Continuing
Methotrexate,Methoblastin PFS,Injection 7.5 mg in 0.3 mL pre-filled syringe,11525N,S,1,5,4,7488,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must be unsuitable for administration of an oral form of methotrexate for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,5 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Celecoxib,GenRx Celecoxib,Capsule 100 mg,8439E,R,1,3,60,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,100 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celecoxib Sandoz,Capsule 100 mg,8439E,R,1,3,60,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,100 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celexi,Capsule 100 mg,8439E,R,1,3,60,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,100 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Blooms the Chemist Celecoxib,Capsule 100 mg,8439E,R,1,3,60,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,100 ,FALSE,FALSE,FALSE,Continuing
Methotrexate,Methoblastin PFS,Injection 15 mg in 0.6 mL pre-filled syringe,11508Q,S,1,5,4,7488,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must be unsuitable for administration of an oral form of methotrexate for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,15 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celexi,Capsule 200 mg,8440F,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,200 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Blooms the Chemist Celecoxib,Capsule 200 mg,8440F,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,200 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celecoxib GH,Capsule 200 mg,8440F,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,200 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12398M,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12398M,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12398M,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug within this treatment cycle, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,APX-Celecoxib,Capsule 200 mg,8440F,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,200 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celecoxib APOTEX,Capsule 200 mg,8440F,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,200 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celecoxib AN,Capsule 200 mg,8440F,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,200 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celecoxib Sandoz,Capsule 200 mg,8440F,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,200 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celecoxib BTC,Capsule 200 mg,8440F,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,200 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celebrex,Capsule 200 mg,8440F,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,200 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,GenRx Celecoxib,Capsule 200 mg,8440F,R,1,3,30,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,200 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celecoxib BTC,Capsule 100 mg,8439E,R,1,3,60,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,100 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celecoxib GH,Capsule 100 mg,8439E,R,1,3,60,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,100 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celaxib,Capsule 100 mg,8439E,R,1,3,60,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,100 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celebrex,Capsule 100 mg,8439E,R,1,3,60,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,100 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celecoxib APOTEX,Capsule 100 mg,8439E,R,1,3,60,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,100 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,APO-Celecoxib,Capsule 100 mg,8439E,R,1,3,60,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,100 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,Celecoxib AN,Capsule 100 mg,8439E,R,1,3,60,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,100 ,FALSE,FALSE,FALSE,Continuing
Celecoxib,APX-Celecoxib,Capsule 100 mg,8439E,R,1,3,60,NA,"<p>Rheumatoid arthritis</p>
<p>The treatment must be for symptomatic treatment.</p>",Rheumatoid arthritis,RA,Restricted,100 ,FALSE,FALSE,FALSE,Continuing
Methotrexate,Methoblastin PFS,injection 20 mg in 0.8 mL pre-filled syringe,11509R,S,1,5,4,7488,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must be unsuitable for administration of an oral form of methotrexate for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Methotrexate,Trexject,Injection 7.5 mg in 0.15 mL pre-filled syringe,11275K,S,4,5,1,7488,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must be unsuitable for administration of an oral form of methotrexate for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,5 ,FALSE,FALSE,FALSE,Continuing
Methotrexate,Trexject,Injection 10 mg in 0.2 mL pre-filled syringe,11283W,S,4,5,1,7488,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must be unsuitable for administration of an oral form of methotrexate for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,12415K,S,1,5,2,11523,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Ustekinumab,Stelara,Injection 45 mg in 0.5 mL,10767Q,A,1,1,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,45 ,FALSE,FALSE,FALSE,Continuing
Ustekinumab,Stelara,Injection 45 mg in 0.5 mL,10767Q,A,1,1,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,45 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Arabloc,Tablet 10 mg,5449T,S,1,5,30,5766,"<p>Severe active psoriatic arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",active psoriatic arthritis,PsA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Ustekinumab,Stelara,Injection 45 mg in 0.5 mL,10774C,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 28 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,45 ,FALSE,FALSE,FALSE,Initial
Ustekinumab,Stelara,Injection 45 mg in 0.5 mL,10774C,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 28 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,45 ,FALSE,FALSE,FALSE,Initial
Ustekinumab,Stelara,Injection 45 mg in 0.5 mL,10774C,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 28 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,45 ,FALSE,FALSE,FALSE,Initial
Ustekinumab,Stelara,Injection 45 mg in 0.5 mL,10774C,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 1 (new patient) restriction to complete 28 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 28 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 28 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 28 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,45 ,FALSE,FALSE,FALSE,Initial
Leflunomide,Leflunomide Sandoz,Tablet 10 mg,5449T,S,1,5,30,5766,"<p>Severe active psoriatic arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",active psoriatic arthritis,PsA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Ataris 10,Tablet 10 mg,8374R,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Ataris 10,Tablet 10 mg,5449T,S,1,5,30,5766,"<p>Severe active psoriatic arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",active psoriatic arthritis,PsA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Arava,Tablet 10 mg,8374R,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Leflunomide generichealth,Tablet 10 mg,5449T,S,1,5,30,5766,"<p>Severe active psoriatic arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",active psoriatic arthritis,PsA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Leflunomide generichealth,Tablet 10 mg,8374R,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Arabloc,Tablet 10 mg,8374R,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Leflunomide Sandoz,Tablet 10 mg,8374R,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Ataris 20,Tablet 20 mg,5450W,S,1,5,30,5766,"<p>Severe active psoriatic arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",active psoriatic arthritis,PsA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,12438P,S,1,5,2,11523,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Ataris 20,Tablet 20 mg,8375T,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Abatacept,Orencia,Powder for I.V. infusion 250 mg,9621J,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of authority application, medical practitioners should request the appropriate number of vials to provide sufficient drug, based on the weight of the patient, for a single infusion.</p>
 <p align=\""justify\"">Up to a maximum of 4 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,250 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia,Powder for I.V. infusion 250 mg,9621J,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months).</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of authority application, medical practitioners should request the appropriate number of vials to provide sufficient drug, based on the weight of the patient, for a single infusion.</p>
 <p align=\""justify\"">Up to a maximum of 4 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,250 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia,Powder for I.V. infusion 250 mg,9621J,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,250 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia,Powder for I.V. infusion 250 mg,9621J,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,250 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia,Powder for I.V. infusion 250 mg,9621J,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,250 ,FALSE,FALSE,FALSE,Continuing
Abatacept,Orencia,Powder for I.V. infusion 250 mg,9621J,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,250 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Arabloc,Tablet 20 mg,5450W,S,1,5,30,5766,"<p>Severe active psoriatic arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",active psoriatic arthritis,PsA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Abatacept,Orencia,Powder for I.V. infusion 250 mg,5605B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of authority application, medical practitioners should request the appropriate number of vials to provide sufficient drug, based on the weight of the patient, for a single infusion.</p>
 <p align=\""justify\"">Up to a maximum of 4 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,250 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia,Powder for I.V. infusion 250 mg,5605B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months).</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of authority application, medical practitioners should request the appropriate number of vials to provide sufficient drug, based on the weight of the patient, for a single infusion.</p>
 <p align=\""justify\"">Up to a maximum of 4 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,250 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia,Powder for I.V. infusion 250 mg,5605B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,250 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia,Powder for I.V. infusion 250 mg,5605B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,250 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia,Powder for I.V. infusion 250 mg,5605B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,250 ,FALSE,FALSE,FALSE,Continuing
Abatacept,Orencia,Powder for I.V. infusion 250 mg,5605B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,250 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Arabloc,Tablet 20 mg,8375T,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Abatacept,Orencia,Injection 125 mg in 1 mL single dose pre-filled syringe,1221G,A,1,5,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,125 ,FALSE,FALSE,FALSE,Continuing
Abatacept,Orencia,Injection 125 mg in 1 mL single dose pre-filled syringe,1221G,A,1,5,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,125 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Leflunomide AN,Tablet 20 mg,8375T,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Abatacept,Orencia,Injection 125 mg in 1 mL single dose pre-filled syringe,1220F,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,125 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia,Injection 125 mg in 1 mL single dose pre-filled syringe,1220F,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of authority application, medical practitioners should request the appropriate number of vials to provide sufficient drug, based on the weight of the patient, for a single infusion.</p>
 <p align=\""justify\"">Up to a maximum of 4 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Initial treatment with an I.V. loading dose: Two completed authority prescriptions must be submitted with the initial application. One prescription must be for the I.V. loading dose for sufficient vials for one dose based on the patient&apos;s weight with no repeats. The second prescription must be written for the subcutaneous formulation, with a maximum quantity of 4 and up to 3 repeats.</p>
 <p align=\""justify\"">Initial treatment with no loading dose: One completed authority prescription must be submitted with the initial application. The prescription must be written with a maximum quantity of 4 and up to 3 repeats.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,125 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia,Injection 125 mg in 1 mL single dose pre-filled syringe,1220F,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months).</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Initial treatment with an I.V. loading dose: Two completed authority prescriptions must be submitted with the initial application. One prescription must be for the I.V. loading dose for sufficient vials for one dose based on the patient&apos;s weight with no repeats. The second prescription must be written for the subcutaneous formulation, with a maximum quantity of 4 and up to 3 repeats.</p>
 <p align=\""justify\"">Initial treatment with no loading dose: One completed authority prescription must be submitted with the initial application. The prescription must be written with a maximum quantity of 4 and up to 3 repeats.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,125 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia,Injection 125 mg in 1 mL single dose pre-filled syringe,1220F,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Initial treatment with an I.V. loading dose: Two completed authority prescriptions must be submitted with the initial application. One prescription must be for the I.V. loading dose for sufficient vials for one dose based on the patient&apos;s weight with no repeats. The second prescription must be written for the subcutaneous formulation, with a maximum quantity of 4 and up to 3 repeats.</p>
 <p align=\""justify\"">Initial treatment with no loading dose: One completed authority prescription must be submitted with the initial application. The prescription must be written with a maximum quantity of 4 and up to 3 repeats.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,125 ,FALSE,FALSE,FALSE,Initial
Leflunomide,Arava,Tablet 20 mg,8375T,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Abatacept,Orencia ClickJect,Injection 125 mg in 1 mL single dose autoinjector,11693K,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,125 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia ClickJect,Injection 125 mg in 1 mL single dose autoinjector,11693K,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of authority application, medical practitioners should request the appropriate number of vials to provide sufficient drug, based on the weight of the patient, for a single infusion.</p>
 <p align=\""justify\"">Up to a maximum of 4 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Initial treatment with an I.V. loading dose: Two completed authority prescriptions must be submitted with the initial application. One prescription must be for the I.V. loading dose for sufficient vials for one dose based on the patient&apos;s weight with no repeats. The second prescription must be written for the subcutaneous formulation, with a maximum quantity of 4 and up to 3 repeats.</p>
 <p align=\""justify\"">Initial treatment with no loading dose: One completed authority prescription must be submitted with the initial application. The prescription must be written with a maximum quantity of 4 and up to 3 repeats.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,125 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia ClickJect,Injection 125 mg in 1 mL single dose autoinjector,11693K,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months).</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Initial treatment with an I.V. loading dose: Two completed authority prescriptions must be submitted with the initial application. One prescription must be for the I.V. loading dose for sufficient vials for one dose based on the patient&apos;s weight with no repeats. The second prescription must be written for the subcutaneous formulation, with a maximum quantity of 4 and up to 3 repeats.</p>
 <p align=\""justify\"">Initial treatment with no loading dose: One completed authority prescription must be submitted with the initial application. The prescription must be written with a maximum quantity of 4 and up to 3 repeats.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,125 ,FALSE,FALSE,FALSE,Initial
Abatacept,Orencia ClickJect,Injection 125 mg in 1 mL single dose autoinjector,11693K,A,1,3,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Initial treatment with an I.V. loading dose: Two completed authority prescriptions must be submitted with the initial application. One prescription must be for the I.V. loading dose for sufficient vials for one dose based on the patient&apos;s weight with no repeats. The second prescription must be written for the subcutaneous formulation, with a maximum quantity of 4 and up to 3 repeats.</p>
 <p align=\""justify\"">Initial treatment with no loading dose: One completed authority prescription must be submitted with the initial application. The prescription must be written with a maximum quantity of 4 and up to 3 repeats.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,125 ,FALSE,FALSE,FALSE,Initial
Leflunomide,Arava,Tablet 20 mg,5450W,S,1,5,30,5766,"<p>Severe active psoriatic arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",active psoriatic arthritis,PsA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Abatacept,Orencia ClickJect,Injection 125 mg in 1 mL single dose autoinjector,11684Y,A,1,5,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,125 ,FALSE,FALSE,FALSE,Continuing
Abatacept,Orencia ClickJect,Injection 125 mg in 1 mL single dose autoinjector,11684Y,A,1,5,4,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,125 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Leflunomide Sandoz,Tablet 20 mg,8375T,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Leflunomide Sandoz,Tablet 20 mg,5450W,S,1,5,30,5766,"<p>Severe active psoriatic arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",active psoriatic arthritis,PsA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Leflunomide,Lunava 20,Tablet 20 mg,8375T,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Leflunomide APOTEX,Tablet 20 mg,8375T,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Leflunomide APOTEX,Tablet 20 mg,5450W,S,1,5,30,5766,"<p>Severe active psoriatic arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",active psoriatic arthritis,PsA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Leflunomide generichealth,Tablet 20 mg,8375T,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug within this treatment cycle, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Lunava 10,Tablet 10 mg,8374R,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Leflunomide generichealth,Tablet 20 mg,5450W,S,1,5,30,5766,"<p>Severe active psoriatic arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",active psoriatic arthritis,PsA,Streamlined,20 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Arava,Tablet 10 mg,5449T,S,1,5,30,5766,"<p>Severe active psoriatic arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",active psoriatic arthritis,PsA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Leflunomide,Leflunomide APOTEX,Tablet 10 mg,5449T,S,1,5,30,5766,"<p>Severe active psoriatic arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",active psoriatic arthritis,PsA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Leflunomide APOTEX,Tablet 10 mg,8374R,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Leflunomide,Leflunomide AN,Tablet 10 mg,8374R,S,1,5,30,5681,"<p>Severe active rheumatoid arthritis</p>
<p>Patient must have previously received, and failed to achieve an adequate response to, one or more disease modifying anti-rheumatic drugs including methotrexate; or</p>
 <p>Patient must be clinically inappropriate for treatment with one or more disease modifying anti-rheumatic drugs including methotrexate; AND</p>
 <p>The treatment must be initiated by a physician.</p>",Severe active rheumatoid arthritis,RA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,12326R,S,1,5,2,11605,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,12438P,S,1,5,2,11523,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled syringe,12327T,S,1,5,2,11634,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 units (on a scale of 0-10) in the BASDAI score combined with at least 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,12326R,S,1,5,2,11605,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug within this treatment cycle, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,12326R,S,1,5,2,11605,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,12438P,S,1,5,2,11523,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,12566J,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Balance of supply for Initial treatment, Continuing treatment or Grandfather patient - subcutaneous form</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial treatment with subcutaneous form restriction to complete 22 weeks initial treatment (intravenous and subcutaneous inclusive); or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment with subcutaneous form restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Grandfather restriction to complete 24 weeks of treatment; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the Initial treatment - subcutaneous form; or</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the Continuing treatment - subcutaneous form; or</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks therapy under Initial PBS-subsidised treatment (Grandfather patient) - subcutaneous form; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,120 ,FALSE,FALSE,TRUE,Grandfathered
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,12577Y,A,2,2,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment with subcutaneous form at weeks 6, 8, 10, 12, 14 and 16</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received 2 intravenous infusions with this drug for this condition at weeks 0 and 2 under Initial 1 (new patient); or</p>
 <p>Patient must have received 2 intravenous infusions with this drug for this condition at weeks 0 and 2 under Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) if changing treatment from another biological medicine to infliximab; or</p>
 <p>Patient must have a concurrent authority application for 2 doses of the intravenous infusion for this condition under either Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months); AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,120 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,12577Y,A,2,2,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Re-initiation with subcutaneous form</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received maintenance treatment with the subcutaneous form of this drug under continuing treatment and have had a treatment break; AND</p>
 <p>Patient must have received 1 intravenous infusion with this drug for this condition at week 0 under Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months); or</p>
 <p>Patient must have received 1 intravenous infusion with this drug for this condition at week 0 under Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months); or</p>
 <p>Patient must have a concurrent authority application for 1 dose of the intravenous infusion for this condition under either Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months); AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,120 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,12553Q,A,2,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial PBS-subsidised treatment (Grandfather patient) - subcutaneous form</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received non-PBS-subsidised treatment with this drug with the subcutaneous form for this condition prior to 1 July 2021; AND</p>
 <p>Patient must have previously received induction treatment consisting of 2 doses with this drug for this condition in the intravenous form; AND</p>
 <p>Patient must be receiving treatment with this drug for this condition at the time of application; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; or</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug in the intravenous form; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">All applications for treatment with this drug for this condition under this restriction must include baseline joint count and ESR and/or CRP as determined at the completion of a 6 month intensive DMARD trial but prior to ceasing DMARD therapy, and measurement of response to the prior course of non-PBS-subsidised therapy with this drug. This assessment must be submitted no later than 4 weeks from the cessation of that treatment course.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">A Grandfathered patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the continuing treatment criteria.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">The patient remains eligible to receive continuing treatment with the same biological medicine in courses of up to 24 weeks providing they continue to sustain an adequate response. It is recommended that a patient be reviewed in the month prior to completing their current course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,120 ,FALSE,FALSE,TRUE,Grandfathered
Infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,12553Q,A,2,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug (in any form) as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; or</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug in the intravenous form; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">The patient remains eligible to receive continuing treatment with the same biological medicine in courses of up to 24 weeks providing they continue to sustain an adequate response. It is recommended that a patient be reviewed within 4 weeks prior to completing their current course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request sufficient quantity for up to 24 weeks of treatment under this restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,120 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,12576X,A,2,2,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment with subcutaneous form at weeks 6, 8, 10, 12, 14 and 16</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received 2 intravenous infusions with this drug for this condition at weeks 0 and 2 under Initial 1 (new patient); or</p>
 <p>Patient must have received 2 intravenous infusions with this drug for this condition at weeks 0 and 2 under Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) if changing treatment from another biological medicine to infliximab; or</p>
 <p>Patient must have a concurrent authority application for 2 doses of the intravenous infusion for this condition under either Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months); AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,120 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,12576X,A,2,2,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Re-initiation with subcutaneous form</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received maintenance treatment with the subcutaneous form of this drug under continuing treatment and have had a treatment break; AND</p>
 <p>Patient must have received 1 intravenous infusion with this drug for this condition at week 0 under Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months); or</p>
 <p>Patient must have received 1 intravenous infusion with this drug for this condition at week 0 under Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months); or</p>
 <p>Patient must have a concurrent authority application for 1 dose of the intravenous infusion for this condition under either Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months); AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,120 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11323Y,A,3,0,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11323Y,A,3,0,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11323Y,A,3,0,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled pen,12568L,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 20 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 20 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled pen,12568L,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 20 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled pen,12568L,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 20 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled pen,12568L,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 20 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy.</p>
 <p align=\""justify\"">Where an assessment is not conducted within these timeframes, the patient will be deemed to have failed to respond, or to have failed to sustain a response to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled pen,12568L,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled pen,12568L,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy.</p>
 <p align=\""justify\"">Where an assessment is not conducted within these timeframes, the patient will be deemed to have failed to respond, or to have failed to sustain a response to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled syringe,12555T,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Balance of supply for Initial treatment, Continuing treatment or Grandfather patient - subcutaneous form</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial treatment with subcutaneous form restriction to complete 22 weeks initial treatment (intravenous and subcutaneous inclusive); or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment with subcutaneous form restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Grandfather restriction to complete 24 weeks of treatment; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the Initial treatment - subcutaneous form; or</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the Continuing treatment - subcutaneous form; or</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks therapy under Initial PBS-subsidised treatment (Grandfather patient) - subcutaneous form; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,120 ,FALSE,FALSE,TRUE,Grandfathered
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11324B,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11324B,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,12327T,S,1,5,2,11634,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 units (on a scale of 0-10) in the BASDAI score combined with at least 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11321W,A,1,2,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 18 to 20 weeks treatment, depending on the dosage regimen; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 18 to 20 weeks treatment, depending on the dosage regimen; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) restriction to complete 18 to 20 weeks treatment, depending on the dosage regimen; AND</p>
 <p>The treatment must provide no more than the balance of up to 18 to 20 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled syringe,12590P,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 20 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 20 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled syringe,12590P,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 20 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled syringe,12590P,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 20 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled syringe,12590P,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 20 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy.</p>
 <p align=\""justify\"">Where an assessment is not conducted within these timeframes, the patient will be deemed to have failed to respond, or to have failed to sustain a response to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled syringe,12590P,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Guselkumab,Tremfya,Injection 100 mg in 1 mL single use pre-filled syringe,12590P,A,1,2,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy.</p>
 <p align=\""justify\"">Where an assessment is not conducted within these timeframes, the patient will be deemed to have failed to respond, or to have failed to sustain a response to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11326D,A,1,2,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 18 to 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 to 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 to 20 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 18 to 20 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,12028C,A,1,5,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug for this condition; AND</p>
 <p>The treatment must not exceed a maximum of 24 weeks with this drug per authorised course under this restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">An adequate response to therapy with this biological medicine is defined as a reduction from baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score by 2 or more units (on a scale of 0-10) and 1 of the following:</p><p align=\""justify\"">(a) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(b) a CRP measurement reduced by at least 20% from baseline.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated CRP level could not be met under an initial treatment restriction, a reduction in the BASDAI score from baseline will suffice for the purposes of administering this continuing treatment restriction.</p>
 <p align=\""justify\"">The patient remains eligible to receive continuing treatment with the same biological medicine in courses of up to 24 weeks providing they continue to sustain an adequate response. It is recommended that a patient be reviewed in the month prior to completing their current course of treatment.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11325C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11325C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 22 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11322X,A,3,0,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months).</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11322X,A,3,0,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11322X,A,3,0,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11514B,S,5,2,1,9188,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,12027B,A,3,0,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had chronic lower back pain and stiffness for 3 or more months that is relieved by exercise but not rest; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must have one or more of the following: (a) enthesitis (heel); (b) uveitis; (c) dactylitis; (d) psoriasis; (e) inflammatory bowel disease; or (f) positive for Human Leukocyte Antigen B27 (HLA-B27); AND</p>
 <p>The condition must not be radiographically evidenced on plain x-ray of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis; AND</p>
 <p>The condition must be non-radiographic axial spondyloarthritis, as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria; AND</p>
 <p>The condition must be sacroiliitis with active inflammation and/or oedema on non-contrast Magnetic Resonance Imaging (MRI); AND</p>
 <p>The condition must have presence of Bone Marrow Oedema (BMO) depicted as a hyperintense signal on a Short Tau Inversion Recovery (STIR) image (or equivalent); AND</p>
 <p>The condition must have BMO depicted as a hypointense signal on a T1 weighted image (without gadolinium); AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">The following must be provided at the time of application and documented in the patient&apos;s medical records:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) C-reactive protein (CRP) level greater than 10 mg per L.</p>
 <p align=\""justify\"">The BASDAI score and CRP level must be no more than 4 weeks old at the time of this application.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,12027B,A,3,0,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 1 (New patient)</p>
<p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had chronic lower back pain and stiffness for 3 or more months that is relieved by exercise but not rest; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must have one or more of the following: (a) enthesitis (heel); (b) uveitis; (c) dactylitis; (d) psoriasis; (e) inflammatory bowel disease; or (f) positive for Human Leukocyte Antigen B27 (HLA-B27); AND</p>
 <p>The condition must not be radiographically evidenced on plain x-ray of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis; AND</p>
 <p>The condition must be non-radiographic axial spondyloarthritis, as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria; AND</p>
 <p>The condition must be sacroiliitis with active inflammation and/or oedema on non-contrast Magnetic Resonance Imaging (MRI); AND</p>
 <p>The condition must have presence of Bone Marrow Oedema (BMO) depicted as a hyperintense signal on a Short Tau Inversion Recovery (STIR) image (or equivalent); AND</p>
 <p>The condition must have BMO depicted as a hypointense signal on a T1 weighted image (without gadolinium); AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response to NSAIDs and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""left\"">The baseline BASDAI score and CRP level must be determined at the completion of the 3-month NSAID and exercise trial, but prior to ceasing NSAID treatment. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">The baseline BASDAI score and CRP level must also be documented in the patient&apos;s medical records.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,12027B,A,3,0,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with biological medicines more than three times for this PBS-indication during the current treatment cycle; AND</p>
 <p>Patient must not have failed PBS-subsidised therapy with this biological medicine for this PBS indication more than once in the current treatment cycle; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">An application for Initial 2 treatment must indicate whether the patient has demonstrated an adequate response (an absence of treatment failure), failed or experienced an intolerance to the most recent supply of biological medicine treatment.</p><p align=\""justify\"">A new baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and C-reactive protein (CRP) level may be provided at the time of this application.</p>
 <p align=\""justify\"">An adequate response to therapy with this biological medicine is defined as a reduction from baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score by 2 or more units (on a scale of 0-10) and 1 of the following:</p><p align=\""justify\"">(a) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(b) a CRP measurement reduced by at least 20% from baseline.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the most recent supply of biological medicine must be conducted following a minimum of 12 weeks of treatment.</p>
 <p align=\""justify\"">BASDAI scores and CRP levels must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">The following must be provided at the time of application and documented in the patient&apos;s medical records:</p><p align=\""justify\"">(a) the BASDAI score; and</p><p align=\""justify\"">(b) the C-reactive protein (CRP) level.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,12040Q,A,1,0,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 18 to 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 to 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 to 20 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 20 weeks treatment; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,12040Q,A,1,0,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Grandfather treatment</p>
<p>Patient must have received non-PBS-subsidised treatment with this drug for this PBS indication prior to 1 June 2020; AND</p>
 <p>Patient must have had chronic lower back pain and stiffness for 3 or more months that was relieved by exercise but not rest, prior to initiating non-PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must have had failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months, prior to initiating non-PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must have had one or more of the following: (a) enthesitis (heel); (b) uveitis; (c) dactylitis; (d) psoriasis; (e) inflammatory bowel disease; or (f) positive for Human Leukocyte Antigen B27 (HLA-B27); prior to initiating non-PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>The condition must not be radiographically evidenced on plain x-ray of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis prior to commencing non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The condition must have been diagnosed as non-radiographic axial spondyloarthritis, as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria, prior to having commenced non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The condition must have been sacroiliitis with active inflammation and/or oedema on non-contrast Magnetic Resonance Imaging (MRI) prior to commencing non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The condition must have had presence of Bone Marrow Oedema (BMO) depicted as a hyperintense signal on a Short Tau Inversion Recovery (STIR) image (or equivalent) prior to commencing non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The condition must have had BMO depicted as a hypointense signal on a T1 weighted image (without gadolinium) prior to commencing non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The treatment must not exceed a maximum of 24 weeks with this drug under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""left\"">The following criteria indicate failure to achieve an adequate response to NSAIDs and must have been demonstrated prior to initiation of non-PBS subsidised treatment with this biological medicine for this condition:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) C-reactive protein (CRP) level greater than 10 mg per L.</p>
 <p align=\""left\"">The BASDAI score and CRP level must have been determined at the completion of the 3-month NSAID and exercise trial, but prior to ceasing NSAID treatment. All measures must have been no more than 1 month old at the time of initiating non-PBS subsidised treatment with this biological medicine for this condition.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">A Grandfathered patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the continuing treatment criteria.</p>
 <p align=\""left\"">The authority application must be made in writing and must include:</p><p align=\""left\"">(a) a completed authority prescription form; and</p><p align=\""left\"">(b) a completed Non-radiographic axial spondyloarthritis Grandfathered PBS Authority Application - Supporting Information Form which seeks details of:</p><p align=\""left\"">(i) a copy of the radiological report confirming the absence of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis; and</p><p align=\""left\"">(ii) a BASDAI score and CRP level that substantiates failure to achieve an adequate response to NSAIDs prior to initiating non-PBS subsidised treatment with this biological medicine for this condition; and</p><p align=\""left\"">(iii) the MRI report; and</p><p align=\""left\"">(iv) the NSAIDs trialled, their doses and duration of treatment. If applicable, the reason a higher dose cannot be used where the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information or details of the contraindication or intolerance according to the relevant TGA-approved Product Information must be included.</p>
 <p align=\""justify\"">The baseline BASDAI score and CRP level must also be documented in the patient&apos;s medical records.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,TRUE,Grandfathered
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,12040Q,A,1,0,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Continuing treatment or Grandfather patient - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Grandfathered treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the continuing treatment restriction or the grandfather restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,TRUE,Grandfathered
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10904X,A,3,0,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10904X,A,3,0,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10904X,A,3,0,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10892G,A,1,2,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 18 to 20 weeks treatment, depending on the dosage regimen; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 18 to 20 weeks treatment, depending on the dosage regimen; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) restriction to complete 18 to 20 weeks treatment, depending on the dosage regimen; AND</p>
 <p>The treatment must provide no more than the balance of up to 18 to 20 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10897M,A,1,2,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 18 to 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 to 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 to 20 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 18 to 20 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10238W,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10238W,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11489Q,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">Each application for subsequent continuing treatment with this drug must include an assessment of the patient&apos;s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11489Q,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,12005W,A,1,5,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug for this condition; AND</p>
 <p>The treatment must not exceed a maximum of 24 weeks with this drug per authorised course under this restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">An adequate response to therapy with this biological medicine is defined as a reduction from baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score by 2 or more units (on a scale of 0-10) and 1 of the following:</p><p align=\""justify\"">(a) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(b) a CRP measurement reduced by at least 20% from baseline.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated CRP level could not be met under an initial treatment restriction, a reduction in the BASDAI score from baseline will suffice for the purposes of administering this continuing treatment restriction.</p>
 <p align=\""justify\"">The patient remains eligible to receive continuing treatment with the same biological medicine in courses of up to 24 weeks providing they continue to sustain an adequate response. It is recommended that a patient be reviewed in the month prior to completing their current course of treatment.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11489Q,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">Each application for subsequent continuing treatment with this drug must include an assessment of the patient&apos;s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11489Q,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11318Q,A,1,2,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 18 to 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 to 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 to 20 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 18 to 20 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,12063X,A,3,0,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had chronic lower back pain and stiffness for 3 or more months that is relieved by exercise but not rest; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must have one or more of the following: (a) enthesitis (heel); (b) uveitis; (c) dactylitis; (d) psoriasis; (e) inflammatory bowel disease; or (f) positive for Human Leukocyte Antigen B27 (HLA-B27); AND</p>
 <p>The condition must not be radiographically evidenced on plain x-ray of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis; AND</p>
 <p>The condition must be non-radiographic axial spondyloarthritis, as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria; AND</p>
 <p>The condition must be sacroiliitis with active inflammation and/or oedema on non-contrast Magnetic Resonance Imaging (MRI); AND</p>
 <p>The condition must have presence of Bone Marrow Oedema (BMO) depicted as a hyperintense signal on a Short Tau Inversion Recovery (STIR) image (or equivalent); AND</p>
 <p>The condition must have BMO depicted as a hypointense signal on a T1 weighted image (without gadolinium); AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">The following must be provided at the time of application and documented in the patient&apos;s medical records:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) C-reactive protein (CRP) level greater than 10 mg per L.</p>
 <p align=\""justify\"">The BASDAI score and CRP level must be no more than 4 weeks old at the time of this application.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,12063X,A,3,0,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 1 (New patient)</p>
<p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had chronic lower back pain and stiffness for 3 or more months that is relieved by exercise but not rest; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must have one or more of the following: (a) enthesitis (heel); (b) uveitis; (c) dactylitis; (d) psoriasis; (e) inflammatory bowel disease; or (f) positive for Human Leukocyte Antigen B27 (HLA-B27); AND</p>
 <p>The condition must not be radiographically evidenced on plain x-ray of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis; AND</p>
 <p>The condition must be non-radiographic axial spondyloarthritis, as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria; AND</p>
 <p>The condition must be sacroiliitis with active inflammation and/or oedema on non-contrast Magnetic Resonance Imaging (MRI); AND</p>
 <p>The condition must have presence of Bone Marrow Oedema (BMO) depicted as a hyperintense signal on a Short Tau Inversion Recovery (STIR) image (or equivalent); AND</p>
 <p>The condition must have BMO depicted as a hypointense signal on a T1 weighted image (without gadolinium); AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response to NSAIDs and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""left\"">The baseline BASDAI score and CRP level must be determined at the completion of the 3-month NSAID and exercise trial, but prior to ceasing NSAID treatment. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">The baseline BASDAI score and CRP level must also be documented in the patient&apos;s medical records.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,12063X,A,3,0,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with biological medicines more than three times for this PBS-indication during the current treatment cycle; AND</p>
 <p>Patient must not have failed PBS-subsidised therapy with this biological medicine for this PBS indication more than once in the current treatment cycle; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">An application for Initial 2 treatment must indicate whether the patient has demonstrated an adequate response (an absence of treatment failure), failed or experienced an intolerance to the most recent supply of biological medicine treatment.</p><p align=\""justify\"">A new baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and C-reactive protein (CRP) level may be provided at the time of this application.</p>
 <p align=\""justify\"">An adequate response to therapy with this biological medicine is defined as a reduction from baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score by 2 or more units (on a scale of 0-10) and 1 of the following:</p><p align=\""justify\"">(a) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(b) a CRP measurement reduced by at least 20% from baseline.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the most recent supply of biological medicine must be conducted following a minimum of 12 weeks of treatment.</p>
 <p align=\""justify\"">BASDAI scores and CRP levels must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">The following must be provided at the time of application and documented in the patient&apos;s medical records:</p><p align=\""justify\"">(a) the BASDAI score; and</p><p align=\""justify\"">(b) the C-reactive protein (CRP) level.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10909E,A,3,0,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10909E,A,3,0,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10909E,A,3,0,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11490R,S,3,2,1,8755,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.<br/><br/></p><p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,3425G,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,3425G,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11487N,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10905Y,A,3,0,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months).</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10905Y,A,3,0,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10905Y,A,3,0,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,12326R,S,1,5,2,11605,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10137M,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10137M,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Injection 200 mg in 1 mL single use pre-filled syringe,10896L,A,1,2,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 18 to 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 to 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 to 20 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 18 to 20 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11320T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11320T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,200 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,12013G,A,1,0,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 18 to 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 to 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 to 20 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 20 weeks treatment; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,12013G,A,1,0,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Grandfather treatment</p>
<p>Patient must have received non-PBS-subsidised treatment with this drug for this PBS indication prior to 1 June 2020; AND</p>
 <p>Patient must have had chronic lower back pain and stiffness for 3 or more months that was relieved by exercise but not rest, prior to initiating non-PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must have had failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months, prior to initiating non-PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must have had one or more of the following: (a) enthesitis (heel); (b) uveitis; (c) dactylitis; (d) psoriasis; (e) inflammatory bowel disease; or (f) positive for Human Leukocyte Antigen B27 (HLA-B27); prior to initiating non-PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>The condition must not be radiographically evidenced on plain x-ray of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis prior to commencing non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The condition must have been diagnosed as non-radiographic axial spondyloarthritis, as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria, prior to having commenced non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The condition must have been sacroiliitis with active inflammation and/or oedema on non-contrast Magnetic Resonance Imaging (MRI) prior to commencing non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The condition must have had presence of Bone Marrow Oedema (BMO) depicted as a hyperintense signal on a Short Tau Inversion Recovery (STIR) image (or equivalent) prior to commencing non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The condition must have had BMO depicted as a hypointense signal on a T1 weighted image (without gadolinium) prior to commencing non-PBS-subsidised treatment with this biological medicine; AND</p>
 <p>The treatment must not exceed a maximum of 24 weeks with this drug under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""left\"">The following criteria indicate failure to achieve an adequate response to NSAIDs and must have been demonstrated prior to initiation of non-PBS subsidised treatment with this biological medicine for this condition:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) C-reactive protein (CRP) level greater than 10 mg per L.</p>
 <p align=\""left\"">The BASDAI score and CRP level must have been determined at the completion of the 3-month NSAID and exercise trial, but prior to ceasing NSAID treatment. All measures must have been no more than 1 month old at the time of initiating non-PBS subsidised treatment with this biological medicine for this condition.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">A Grandfathered patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the continuing treatment criteria.</p>
 <p align=\""left\"">The authority application must be made in writing and must include:</p><p align=\""left\"">(a) a completed authority prescription form; and</p><p align=\""left\"">(b) a completed Non-radiographic axial spondyloarthritis Grandfathered PBS Authority Application - Supporting Information Form which seeks details of:</p><p align=\""left\"">(i) a copy of the radiological report confirming the absence of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis; and</p><p align=\""left\"">(ii) a BASDAI score and CRP level that substantiates failure to achieve an adequate response to NSAIDs prior to initiating non-PBS subsidised treatment with this biological medicine for this condition; and</p><p align=\""left\"">(iii) the MRI report; and</p><p align=\""left\"">(iv) the NSAIDs trialled, their doses and duration of treatment. If applicable, the reason a higher dose cannot be used where the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information or details of the contraindication or intolerance according to the relevant TGA-approved Product Information must be included.</p>
 <p align=\""justify\"">The baseline BASDAI score and CRP level must also be documented in the patient&apos;s medical records.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,TRUE,Grandfathered
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,12013G,A,1,0,2,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Continuing treatment or Grandfather patient - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Grandfathered treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the continuing treatment restriction or the grandfather restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,200 ,FALSE,FALSE,TRUE,Grandfathered
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug within this treatment cycle, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,12554R,A,2,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial PBS-subsidised treatment (Grandfather patient) - subcutaneous form</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received non-PBS-subsidised treatment with this drug with the subcutaneous form for this condition prior to 1 July 2021; AND</p>
 <p>Patient must have previously received induction treatment consisting of 2 doses with this drug for this condition in the intravenous form; AND</p>
 <p>Patient must be receiving treatment with this drug for this condition at the time of application; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; or</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug in the intravenous form; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">All applications for treatment with this drug for this condition under this restriction must include baseline joint count and ESR and/or CRP as determined at the completion of a 6 month intensive DMARD trial but prior to ceasing DMARD therapy, and measurement of response to the prior course of non-PBS-subsidised therapy with this drug. This assessment must be submitted no later than 4 weeks from the cessation of that treatment course.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">A Grandfathered patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the continuing treatment criteria.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">The patient remains eligible to receive continuing treatment with the same biological medicine in courses of up to 24 weeks providing they continue to sustain an adequate response. It is recommended that a patient be reviewed in the month prior to completing their current course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,120 ,FALSE,FALSE,TRUE,Grandfathered
Infliximab,Remsima SC,Solution for injection 120 mg in 1 mL pre-filled pen,12554R,A,2,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment with subcutaneous form or switching from intravenous form to subcutaneous form</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug (in any form) as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; or</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug in the intravenous form; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">The patient remains eligible to receive continuing treatment with the same biological medicine in courses of up to 24 weeks providing they continue to sustain an adequate response. It is recommended that a patient be reviewed within 4 weeks prior to completing their current course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request sufficient quantity for up to 24 weeks of treatment under this restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,120 ,FALSE,FALSE,FALSE,Continuing
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11319R,A,3,0,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11319R,A,3,0,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,200 ,FALSE,FALSE,FALSE,Initial
Certolizumab,Cimzia,Solution for injection 200 mg in 1 mL pre-filled pen,11319R,A,3,0,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 18 to 20 weeks of treatment, depending on the dosage regimen, under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,200 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Initial 1 (new patient) restriction to complete 18 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 18 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,12438P,S,1,5,2,11523,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11498E,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under the first continuing treatment restriction, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11497D,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under the first continuing treatment restriction, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11361Y,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11361Y,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11361Y,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11361Y,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 22 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11521J,A,1,5,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug for this condition; AND</p>
 <p>The treatment must not exceed a maximum of 24 weeks with this drug per authorised course under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">An adequate response to therapy with this biological medicine is defined as a reduction from baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score by 2 or more units (on a scale of 0-10) and 1 of the following:</p><p align=\""justify\"">(a) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(b) a CRP measurement reduced by at least 20% from baseline.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated CRP level could not be met under an initial treatment restriction, a reduction in the BASDAI score from baseline will suffice for the purposes of administering this continuing treatment restriction.</p>
 <p align=\""justify\"">The patient remains eligible to receive continuing treatment with the same biological medicine in courses of up to 24 weeks providing they continue to sustain an adequate response. It is recommended that a patient be reviewed in the month prior to completing their current course of treatment.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11521J,A,1,5,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment ; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11482H,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">Each application for subsequent continuing treatment with this drug must include an assessment of the patient&apos;s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11482H,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11538G,A,1,3,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11538G,A,1,3,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 1 (New patient)</p>
<p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had chronic lower back pain and stiffness for 3 or more months that is relieved by exercise but not rest; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must have one or more of the following: (a) enthesitis (heel); (b) uveitis; (c) dactylitis; (d) psoriasis; (e) inflammatory bowel disease; or (f) positive for Human Leukocyte Antigen B27 (HLA-B27); AND</p>
 <p>The condition must not be radiographically evidenced on plain x-ray of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis; AND</p>
 <p>The condition must be non-radiographic axial spondyloarthritis, as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria; AND</p>
 <p>The condition must be sacroiliitis with active inflammation and/or oedema on non-contrast Magnetic Resonance Imaging (MRI); AND</p>
 <p>The condition must have presence of Bone Marrow Oedema (BMO) depicted as a hyperintense signal on a Short Tau Inversion Recovery (STIR) image (or equivalent); AND</p>
 <p>The condition must have BMO depicted as a hypointense signal on a T1 weighted image (without gadolinium); AND</p>
 <p>The treatment must not exceed a maximum of 16 weeks with this drug under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response to NSAIDs and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""left\"">The baseline BASDAI score and CRP level must be determined at the completion of the 3-month NSAID and exercise trial, but prior to ceasing NSAID treatment. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">The baseline BASDAI score and CRP level must also be documented in the patient&apos;s medical records.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11538G,A,1,3,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had chronic lower back pain and stiffness for 3 or more months that is relieved by exercise but not rest; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must have one or more of the following: (a) enthesitis (heel); (b) uveitis; (c) dactylitis; (d) psoriasis; (e) inflammatory bowel disease; or (f) positive for Human Leukocyte Antigen B27 (HLA-B27); AND</p>
 <p>The condition must not be radiographically evidenced on plain x-ray of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis; AND</p>
 <p>The condition must be non-radiographic axial spondyloarthritis, as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria; AND</p>
 <p>The condition must be sacroiliitis with active inflammation and/or oedema on non-contrast Magnetic Resonance Imaging (MRI); AND</p>
 <p>The condition must have presence of Bone Marrow Oedema (BMO) depicted as a hyperintense signal on a Short Tau Inversion Recovery (STIR) image (or equivalent); AND</p>
 <p>The condition must have BMO depicted as a hypointense signal on a T1 weighted image (without gadolinium); AND</p>
 <p>The treatment must not exceed a maximum of 16 weeks duration under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">The following must be provided at the time of application and documented in the patient&apos;s medical records:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) C-reactive protein (CRP) level greater than 10 mg per L.</p>
 <p align=\""justify\"">The BASDAI score and CRP level must be no more than 4 weeks old at the time of this application.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11538G,A,1,3,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 2 (Change or re-commencement of treatment after a break of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with biological medicines more than three times for this PBS-indication during the current treatment cycle; AND</p>
 <p>The treatment must not exceed a maximum of 16 weeks with this drug under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis; AND</p>
 <p>Patient must not have failed PBS-subsidised therapy with this biological medicine for this PBS indication more than once in the current treatment cycle.</p>

 <p align=\""justify\"">An application for Initial 2 treatment must indicate whether the patient has demonstrated an adequate response (an absence of treatment failure), failed or experienced an intolerance to the most recent supply of biological medicine treatment.</p><p align=\""justify\"">A new baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and C-reactive protein (CRP) level may be provided at the time of this application.</p>
 <p align=\""justify\"">An adequate response to therapy with this biological medicine is defined as a reduction from baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score by 2 or more units (on a scale of 0-10) and 1 of the following:</p><p align=\""justify\"">(a) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(b) a CRP measurement reduced by at least 20% from baseline.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the most recent supply of biological medicine must be conducted following a minimum of 12 weeks of treatment.</p>
 <p align=\""justify\"">BASDAI scores and CRP levels must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">The following must be provided at the time of application and documented in the patient&apos;s medical records:</p><p align=\""justify\"">(a) the BASDAI score; and</p><p align=\""justify\"">(b) the C-reactive protein (CRP) level.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3432P,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3432P,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11375Q,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11375Q,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11372M,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11372M,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11372M,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11372M,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11514B,S,5,2,1,9188,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11373N,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11373N,A,1,5,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11488P,S,5,3,1,9621,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 22 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3430M,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3430M,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3430M,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3430M,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3426H,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) -  balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3426H,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3426H,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, or continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3426H,A,1,3,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,12327T,S,1,5,2,11634,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 units (on a scale of 0-10) in the BASDAI score combined with at least 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3428K,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3428K,A,1,5,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",Severe active rheumatoid arthritis,RA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11486M,S,5,3,1,9481,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug within this treatment cycle, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3434R,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3434R,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3434R,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3434R,A,1,3,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 22 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,11560K,A,1,3,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial 1 (New patient), Initial 2 (Change or re-commencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,11560K,A,1,3,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 1 (New patient)</p>
<p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had chronic lower back pain and stiffness for 3 or more months that is relieved by exercise but not rest; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must have one or more of the following: (a) enthesitis (heel); (b) uveitis; (c) dactylitis; (d) psoriasis; (e) inflammatory bowel disease; or (f) positive for Human Leukocyte Antigen B27 (HLA-B27); AND</p>
 <p>The condition must not be radiographically evidenced on plain x-ray of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis; AND</p>
 <p>The condition must be non-radiographic axial spondyloarthritis, as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria; AND</p>
 <p>The condition must be sacroiliitis with active inflammation and/or oedema on non-contrast Magnetic Resonance Imaging (MRI); AND</p>
 <p>The condition must have presence of Bone Marrow Oedema (BMO) depicted as a hyperintense signal on a Short Tau Inversion Recovery (STIR) image (or equivalent); AND</p>
 <p>The condition must have BMO depicted as a hypointense signal on a T1 weighted image (without gadolinium); AND</p>
 <p>The treatment must not exceed a maximum of 16 weeks with this drug under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response to NSAIDs and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""left\"">The baseline BASDAI score and CRP level must be determined at the completion of the 3-month NSAID and exercise trial, but prior to ceasing NSAID treatment. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">The baseline BASDAI score and CRP level must also be documented in the patient&apos;s medical records.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,11560K,A,1,3,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 3 (Recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had chronic lower back pain and stiffness for 3 or more months that is relieved by exercise but not rest; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must have one or more of the following: (a) enthesitis (heel); (b) uveitis; (c) dactylitis; (d) psoriasis; (e) inflammatory bowel disease; or (f) positive for Human Leukocyte Antigen B27 (HLA-B27); AND</p>
 <p>The condition must not be radiographically evidenced on plain x-ray of Grade II bilateral sacroiliitis or Grade III or IV unilateral sacroiliitis; AND</p>
 <p>The condition must be non-radiographic axial spondyloarthritis, as defined by Assessment of Spondyloarthritis International Society (ASAS) criteria; AND</p>
 <p>The condition must be sacroiliitis with active inflammation and/or oedema on non-contrast Magnetic Resonance Imaging (MRI); AND</p>
 <p>The condition must have presence of Bone Marrow Oedema (BMO) depicted as a hyperintense signal on a Short Tau Inversion Recovery (STIR) image (or equivalent); AND</p>
 <p>The condition must have BMO depicted as a hypointense signal on a T1 weighted image (without gadolinium); AND</p>
 <p>The treatment must not exceed a maximum of 16 weeks duration under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">The following must be provided at the time of application and documented in the patient&apos;s medical records:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) C-reactive protein (CRP) level greater than 10 mg per L.</p>
 <p align=\""justify\"">The BASDAI score and CRP level must be no more than 4 weeks old at the time of this application.</p>
 <p align=\""left\"">If the requirement to demonstrate an elevated CRP level could not be met, the reason must be stated in the application. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,11560K,A,1,3,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Initial treatment - Initial 2 (Change or re-commencement of treatment after a break of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with biological medicines more than three times for this PBS-indication during the current treatment cycle; AND</p>
 <p>The treatment must not exceed a maximum of 16 weeks with this drug under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis; AND</p>
 <p>Patient must not have failed PBS-subsidised therapy with this biological medicine for this PBS indication more than once in the current treatment cycle.</p>

 <p align=\""justify\"">An application for Initial 2 treatment must indicate whether the patient has demonstrated an adequate response (an absence of treatment failure), failed or experienced an intolerance to the most recent supply of biological medicine treatment.</p><p align=\""justify\"">A new baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and C-reactive protein (CRP) level may be provided at the time of this application.</p>
 <p align=\""justify\"">An adequate response to therapy with this biological medicine is defined as a reduction from baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score by 2 or more units (on a scale of 0-10) and 1 of the following:</p><p align=\""justify\"">(a) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(b) a CRP measurement reduced by at least 20% from baseline.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the most recent supply of biological medicine must be conducted following a minimum of 12 weeks of treatment.</p>
 <p align=\""justify\"">BASDAI scores and CRP levels must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">The assessment of the patient&apos;s response to the initial course of treatment must be conducted following a minimum of 12 weeks of treatment and no later than 4 weeks from the cessation of that treatment course. If the response assessment is not conducted within these timeframes, the patient will be deemed to have failed this course of treatment in this treatment cycle.</p>
 <p align=\""justify\"">The following must be provided at the time of application and documented in the patient&apos;s medical records:</p><p align=\""justify\"">(a) the BASDAI score; and</p><p align=\""justify\"">(b) the C-reactive protein (CRP) level.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3436W,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,3436W,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11365E,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11365E,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11365E,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11365E,A,1,3,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,50 ,FALSE,FALSE,FALSE,Initial
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11376R,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled pen,11376R,A,1,5,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11483J,S,3,2,1,9975,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.<br/><br/></p><p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,11516D,A,1,5,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug for this condition; AND</p>
 <p>The treatment must not exceed a maximum of 24 weeks with this drug per authorised course under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>

 <p align=\""justify\"">An adequate response to therapy with this biological medicine is defined as a reduction from baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score by 2 or more units (on a scale of 0-10) and 1 of the following:</p><p align=\""justify\"">(a) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(b) a CRP measurement reduced by at least 20% from baseline.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated CRP level could not be met under an initial treatment restriction, a reduction in the BASDAI score from baseline will suffice for the purposes of administering this continuing treatment restriction.</p>
 <p align=\""justify\"">The patient remains eligible to receive continuing treatment with the same biological medicine in courses of up to 24 weeks providing they continue to sustain an adequate response. It is recommended that a patient be reviewed in the month prior to completing their current course of treatment.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Golimumab,Simponi,Injection 50 mg in 0.5 mL single use pre-filled syringe,11516D,A,1,5,1,NA,"<p>Non-radiographic axial spondyloarthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment ; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.</p>",Non-radiographic axial spondyloarthritis,nr-axSpA,Authority,50 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11481G,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11487N,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Initial 1 (new patient) restriction to complete 18 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 18 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 22 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,12415K,S,1,5,2,11523,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Initial 1 (new patient) restriction to complete 18 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 18 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11498E,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under the first continuing treatment restriction, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,12327T,S,1,5,2,11634,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 units (on a scale of 0-10) in the BASDAI score combined with at least 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Renflexis,Powder for I.V. infusion 100 mg,11515C,S,5,2,1,9472,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11481G,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11497D,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under the first continuing treatment restriction, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11515C,S,5,2,1,9472,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11488P,S,5,3,1,9621,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 22 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9034L,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug within this treatment cycle, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled syringe,8737W,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 22 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11486M,S,5,3,1,9481,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 22 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Initial 1 (new patient) restriction to complete 18 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 18 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,5753T,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11483J,S,3,2,1,9975,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.<br/><br/></p><p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11490R,S,3,2,1,8755,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.<br/><br/></p><p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11482H,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">Each application for subsequent continuing treatment with this drug must include an assessment of the patient&apos;s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,11482H,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 22 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6397Q,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,12329X,S,1,5,2,11605,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Initial 1 (new patient) restriction to complete 18 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 18 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Inflectra,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug within this treatment cycle, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,11482H,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">Each application for subsequent continuing treatment with this drug must include an assessment of the patient&apos;s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,11482H,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,8741C,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12430F,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12430F,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12430F,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply.</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 22 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5757B,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,11498E,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under the first continuing treatment restriction, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 22 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,5756Y,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,11497D,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under the first continuing treatment restriction, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,12329X,S,1,5,2,11605,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Upadacitinib,Rinvoq,Tablet 15 mg,11979L,A,1,5,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Patient must be aged 18 years or older.</p>",Severe active rheumatoid arthritis,RA,Authority,15 ,FALSE,FALSE,FALSE,Continuing
Upadacitinib,Rinvoq,Tablet 15 mg,11979L,A,1,5,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response must be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be determined on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker must be used to determine response.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,15 ,FALSE,FALSE,FALSE,Continuing
Upadacitinib,Rinvoq,Tablet 15 mg,11989B,A,1,3,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity.</p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs.</p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application.</p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response to DMARD treatment and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour and/or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response must be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be determined on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker must be used to determine response.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,15 ,FALSE,FALSE,FALSE,Initial
Upadacitinib,Rinvoq,Tablet 15 mg,11989B,A,1,3,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count, ESR and/or CRP must be no more than 4 weeks old at the time of application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response must be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be determined on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker must be used to determine response.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,15 ,FALSE,FALSE,FALSE,Initial
Upadacitinib,Rinvoq,Tablet 15 mg,11989B,A,1,3,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,15 ,FALSE,FALSE,FALSE,Initial
Upadacitinib,Rinvoq,Tablet 15 mg,11989B,A,1,3,28,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, conducted within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response must be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be determined on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker must be used to determine response.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,15 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">A maximum quantity and number of repeats to provide for an initial course of this drug consisting of 3 doses at 5 mg per kg body weight per dose to be administered at weeks 0, 2 and 6, will be authorised.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Initial 1 (new patient) restriction to complete 18 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 18 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6448J,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 18 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,11487N,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 22 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 22 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 22 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 22 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Initial
Infliximab,Remicade,Powder for I.V. infusion 100 mg,6496X,A,1,0,1,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg eight weekly.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Severe Psoriatic Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either Initial 1, Initial 2, or Initial 3 treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,11489Q,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials, based on the weight of the patient, to provide for infusions at a dose of 5 mg per kg.</p>
 <p align=\""justify\"">Up to a maximum of 3 repeats will be authorised.</p>
 <p align=\""justify\"">Each application for subsequent continuing treatment with this drug must include an assessment of the patient&apos;s response to the prior course of therapy. If the response assessment is not provided at the time of application the patient will be deemed to have failed this course of treatment, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,11489Q,A,1,0,1,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Infliximab,Remicade,Powder for I.V. infusion 100 mg,11481G,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">At the time of the authority application, medical practitioners should request the appropriate quantity of vials to provide sufficient drug, based on the weight of the patient, for a single infusion at a dose of 3 mg per kg.</p>
 <p>Up to a maximum of 2 repeats will be authorised.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,100 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.8 mL pre-filled syringe,9077R,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug within this treatment cycle, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12361N,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12361N,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12361N,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,11805H,S,2,1,1,9446,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,500 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,12329X,S,1,5,2,11605,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,11800C,S,4,0,1,9336,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Streamlined,500 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,11800C,S,4,0,1,9539,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>",active microscopic polyangiitis,MPA,Streamlined,500 ,FALSE,TRUE,FALSE,Re-induction
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,12328W,S,1,5,2,11634,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 units (on a scale of 0-10) in the BASDAI score combined with at least 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,12415K,S,1,5,2,11523,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,9611W,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,9611W,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to respond to at least 1 PBS-subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient whose most recent course of PBS-subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Initial
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,9611W,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,9611W,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have failed to respond to at least 1 PBS-subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient whose most recent course of PBS-subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Initial
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,9611W,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must have failed to respond to at least 1 PBS-subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient whose most recent course of PBS-subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,12329X,S,1,5,2,11605,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,11804G,S,4,0,1,9640,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Streamlined,500 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,11804G,S,4,0,1,9641,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>",active microscopic polyangiitis,MPA,Streamlined,500 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,11790M,S,2,1,1,9611,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,500 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,9544H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,9544H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to respond to at least 1 PBS-subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient whose most recent course of PBS-subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Initial
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,9544H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,9544H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have failed to respond to at least 1 PBS-subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient whose most recent course of PBS-subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Initial
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,9544H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must have failed to respond to at least 1 PBS-subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient whose most recent course of PBS-subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Initial
Rituximab,Riximyo,Solution for I.V. infusion 100 mg in 10 mL,11813R,S,3,0,2,9336,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Streamlined,100 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Riximyo,Solution for I.V. infusion 100 mg in 10 mL,11813R,S,3,0,2,9539,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>",active microscopic polyangiitis,MPA,Streamlined,100 ,FALSE,TRUE,FALSE,Re-induction
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,12328W,S,1,5,2,11634,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 units (on a scale of 0-10) in the BASDAI score combined with at least 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Rituximab,Riximyo,Solution for I.V. infusion 100 mg in 10 mL,11810N,S,3,0,2,9640,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Streamlined,100 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Riximyo,Solution for I.V. infusion 100 mg in 10 mL,11810N,S,3,0,2,9641,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>",active microscopic polyangiitis,MPA,Streamlined,100 ,FALSE,TRUE,FALSE,Re-induction
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Rituximab,Riximyo,Solution for I.V. infusion 100 mg in 10 mL,10583B,A,1,0,2,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,100 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Riximyo,Solution for I.V. infusion 100 mg in 10 mL,10583B,A,1,0,2,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,100 ,TRUE,FALSE,FALSE,Initial
Rituximab,Riximyo,Solution for I.V. infusion 100 mg in 10 mL,10583B,A,1,0,2,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,100 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Riximyo,Solution for I.V. infusion 100 mg in 10 mL,10583B,A,1,0,2,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,100 ,TRUE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9101B,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Rituximab,Riximyo,Solution for I.V. infusion 100 mg in 10 mL,10591K,A,1,0,2,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,100 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Riximyo,Solution for I.V. infusion 100 mg in 10 mL,10591K,A,1,0,2,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,100 ,TRUE,FALSE,FALSE,Initial
Rituximab,Riximyo,Solution for I.V. infusion 100 mg in 10 mL,10591K,A,1,0,2,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,100 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Riximyo,Solution for I.V. infusion 100 mg in 10 mL,10591K,A,1,0,2,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,100 ,TRUE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 100 mg in 10 mL,10583B,A,1,0,2,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,100 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Truxima,Solution for I.V. infusion 100 mg in 10 mL,10583B,A,1,0,2,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,100 ,TRUE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 100 mg in 10 mL,10583B,A,1,0,2,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,100 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Truxima,Solution for I.V. infusion 100 mg in 10 mL,10583B,A,1,0,2,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,100 ,TRUE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 100 mg in 10 mL,10591K,A,1,0,2,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,100 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Truxima,Solution for I.V. infusion 100 mg in 10 mL,10591K,A,1,0,2,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,100 ,TRUE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 100 mg in 10 mL,10591K,A,1,0,2,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,100 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Truxima,Solution for I.V. infusion 100 mg in 10 mL,10591K,A,1,0,2,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,100 ,TRUE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12362P,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12362P,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12362P,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12362P,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 100 mg in 10 mL,11813R,S,3,0,2,9336,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Streamlined,100 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Truxima,Solution for I.V. infusion 100 mg in 10 mL,11813R,S,3,0,2,9539,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>",active microscopic polyangiitis,MPA,Streamlined,100 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,9611W,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,9611W,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to respond to at least 1 PBS-subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient whose most recent course of PBS-subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,9611W,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,9611W,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have failed to respond to at least 1 PBS-subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient whose most recent course of PBS-subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,9611W,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must have failed to respond to at least 1 PBS-subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient whose most recent course of PBS-subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12376J,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12376J,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12376J,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12376J,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12429E,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12429E,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12429E,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12429E,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 100 mg in 10 mL,11810N,S,3,0,2,9640,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Streamlined,100 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Truxima,Solution for I.V. infusion 100 mg in 10 mL,11810N,S,3,0,2,9641,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>",active microscopic polyangiitis,MPA,Streamlined,100 ,FALSE,TRUE,FALSE,Re-induction
Ciclosporin,Neoral 25,Capsule 25 mg,6352H,S,4,5,30,9742,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,25 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12375H,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12375H,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12375H,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug within this treatment cycle, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Ciclosporin,Neoral 25,Capsule 25 mg,5634M,S,4,5,30,6638,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,25 ,FALSE,FALSE,FALSE,Continuing
Ciclosporin,Cyclosporin Sandoz,Capsule 25 mg,6352H,S,4,5,30,9742,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,25 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,9544H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,9544H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to respond to at least 1 PBS-subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised treatment with this drug was approved under either of the Initial 1, Initial 2, Initial 3, first or subsequent continuing treatment restrictions, it is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient whose most recent course of PBS-subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,9544H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">A patient may qualify to receive a further course of treatment (every 24 weeks) with this drug provided they have demonstrated an adequate response to treatment following a minimum of 12 weeks after the first infusion of their most recent treatment with this drug. The demonstration of response must be submitted within 4 weeks of assessment.</p>
 <p align=\""justify\"">It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,9544H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have failed to respond to at least 1 PBS-subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient whose most recent course of PBS-subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,9544H,A,1,0,1,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must have failed to respond to at least 1 PBS-subsidised tumour necrosis factor (TNF) alfa antagonist for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 2 infusions of this drug under this restriction; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than one month old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form(s); and</p><p align=\""justify\"">(2) a completed Rheumatoid Arthritis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">It is recommended that an assessment of a patient&apos;s response is conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from the completion of the most recent course of treatment.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response from the most recent course of biological medicine therapy following a minimum of 12 weeks in therapy. It is recommended that an application for the continuing treatment is submitted to the Department of Human Services no later than 1 month from the date of completion of the most recent course of treatment. This is to ensure continuity of treatment for those who meet the continuing restriction for PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">Where a response assessment is not provided within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">A patient whose most recent course of PBS-subsidised therapy was with this drug and whose response to this treatment is demonstrated at 12 weeks, may apply for a further course of this drug under the First continuing treatment restriction.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to this drug and who qualifies to trial an alternate biological medicine according to the interchangeability arrangements for biological medicines for the treatment of severe rheumatoid arthritis, may do so without having to have a 22 week treatment-free period.</p>",Severe active rheumatoid arthritis,RA,Authority,500 ,FALSE,FALSE,FALSE,Initial
Ciclosporin,Cyclosporin Sandoz,Capsule 25 mg,5634M,S,4,5,30,6638,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,25 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,11805H,S,2,1,1,9446,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,500 ,FALSE,FALSE,FALSE,Continuing
Ciclosporin,Neoral 100,Capsule 100 mg,6354K,S,4,5,30,9742,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,12217B,A,1,1,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 units (on a scale of 0-10) in the BASDAI score combined with at least 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 4 weeks old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,80 ,FALSE,FALSE,FALSE,Initial
Ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,12217B,A,1,1,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,80 ,FALSE,FALSE,FALSE,Initial
Ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,12217B,A,1,1,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application Form which includes the following:</p><p align=\""justify\"">(i) details of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a BASDAI score.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,80 ,FALSE,FALSE,FALSE,Initial
Ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,12217B,A,1,1,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; and</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The baseline BASDAI score and ESR or CRP level must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. All measurements must be no more than 4 weeks old at the time of initial application.</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application Form which includes the following:</p><p align=\""justify\"">(i) details of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a baseline BASDAI score; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form; and</p><p align=\""justify\"">(iv) baseline ESR and/or CRP level</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,80 ,FALSE,FALSE,FALSE,Initial
Ciclosporin,Neoral 100,Capsule 100 mg,5636P,S,4,5,30,6638,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Ciclosporin,Cyclosporin Sandoz,Capsule 100 mg,6354K,S,4,5,30,9742,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,11800C,S,4,0,1,9336,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Streamlined,500 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,11800C,S,4,0,1,9539,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>",active microscopic polyangiitis,MPA,Streamlined,500 ,FALSE,TRUE,FALSE,Re-induction
Ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,12209N,A,1,2,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,80 ,FALSE,FALSE,FALSE,Continuing
Ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,12209N,A,1,2,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 units (on a scale of 0-10) in the BASDAI score combined with at least 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 4 weeks old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within these timeframes, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,80 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12390D,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12390D,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12390D,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,11623R,A,1,2,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 20 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count, ESR and/or CRP must be no more than 4 weeks old at the time of application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,80 ,FALSE,FALSE,FALSE,Initial
Ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,11623R,A,1,2,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 20 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,80 ,FALSE,FALSE,FALSE,Initial
Ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,11623R,A,1,2,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 20 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 20 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 20 weeks treatment available under the above restrictions.</p>",psoriatic arthritis,PsA,Authority,80 ,FALSE,FALSE,FALSE,Initial
Ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,11623R,A,1,2,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 20 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application: </p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,80 ,FALSE,FALSE,FALSE,Initial
Ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,11623R,A,1,2,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction.</p>",psoriatic arthritis,PsA,Authority,80 ,FALSE,FALSE,FALSE,Continuing
Ixekizumab,Taltz,Injection 80 mg in 1 mL single dose pre-filled pen,11623R,A,1,2,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form(s); and</p><p align=\""justify\"">(b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,80 ,FALSE,FALSE,FALSE,Continuing
Ciclosporin,Cyclosporin Sandoz,Capsule 100 mg,5636P,S,4,5,30,6638,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,10593M,A,1,0,1,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,500 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,10593M,A,1,0,1,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,500 ,TRUE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,10593M,A,1,0,1,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,500 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,10593M,A,1,0,1,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,500 ,TRUE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,11804G,S,4,0,1,9640,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Streamlined,500 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,11804G,S,4,0,1,9641,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>",active microscopic polyangiitis,MPA,Streamlined,500 ,FALSE,TRUE,FALSE,Re-induction
Ciclosporin,Neoral,"Oral liquid 100 mg per mL, 50 mL",5633L,S,4,5,1,6638,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12363Q,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12363Q,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled pen,12363Q,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,10576P,A,1,0,1,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,500 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,10576P,A,1,0,1,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,500 ,TRUE,FALSE,FALSE,Initial
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,10576P,A,1,0,1,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,500 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,10576P,A,1,0,1,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,500 ,TRUE,FALSE,FALSE,Initial
Ciclosporin,Neoral,"Oral liquid 100 mg per mL, 50 mL",6125J,S,4,5,1,9742,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,100 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Truxima,Solution for I.V. infusion 500 mg in 50 mL,11790M,S,2,1,1,9611,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>The treatment must be given concomitantly with methotrexate at a dose of at least 7.5 mg weekly; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Streamlined,500 ,FALSE,FALSE,FALSE,Continuing
Ciclosporin,Cyclosporin Sandoz,Capsule 50 mg,5635N,S,4,5,30,6638,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,50 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,10576P,A,1,0,1,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,500 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,10576P,A,1,0,1,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,500 ,TRUE,FALSE,FALSE,Initial
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,10576P,A,1,0,1,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,500 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,10576P,A,1,0,1,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,500 ,TRUE,FALSE,FALSE,Initial
Ciclosporin,Cyclosporin Sandoz,Capsule 50 mg,6353J,S,4,5,30,9742,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,50 ,FALSE,FALSE,FALSE,Continuing
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,10593M,A,1,0,1,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,500 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,10593M,A,1,0,1,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,500 ,TRUE,FALSE,FALSE,Initial
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,10593M,A,1,0,1,NA,"<p>Severe active microscopic polyangiitis</p>
<p>Re-induction of remission</p>
<p>The treatment must be for the re-induction of remission; AND</p>
 <p>Patient must have previously received and responded to this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance therapy.</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active microscopic polyangiitis,MPA,Authority,500 ,FALSE,TRUE,FALSE,Re-induction
Rituximab,Riximyo,Solution for I.V. infusion 500 mg in 50 mL,10593M,A,1,0,1,NA,"<p>Severe active granulomatosis with polyangiitis (Wegeners granulomatosis)</p>
<p>Induction of remission</p>
<p>The treatment must be for the induction of remission; AND</p>
 <p>Patient must not have previously received this drug for this condition; AND</p>
 <p>The treatment must in combination with glucocorticoids; AND</p>
 <p>Patient must be at risk of end-organ damage or mortality; AND</p>
 <p>Patient must be contraindicated, refractory or unable to tolerate cyclophosphamide.</p>

 <p align=\""left\"">Diagnosis should be made according to the Chapel Hill Consensus Conference Nomenclature of the Vasculitides with anti-neutrophil cytoplasmic antibody (ANCA) positive serology. </p>
 <p align=\""justify\"">This drug is not PBS-subsidised for maintenance of remission</p>
 <p align=\""justify\"">The authority application must be made in writing</p>",active granulomatosis with polyangiitis (Wegeners granulomatosis),GPA,Authority,500 ,TRUE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Ciclosporin,Neoral 50,Capsule 50 mg,6353J,S,4,5,30,9742,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,50 ,FALSE,FALSE,FALSE,Continuing
Ciclosporin,Neoral 50,Capsule 50 mg,5635N,S,4,5,30,6638,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,50 ,FALSE,FALSE,FALSE,Continuing
Ciclosporin,Neoral 10,Capsule 10 mg,6232B,S,2,5,60,9742,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Ciclosporin,Neoral 10,Capsule 10 mg,5632K,S,2,5,60,6638,"<p>Severe active rheumatoid arthritis</p>
<p>Management (initiation, stabilisation and review of therapy)</p>
<p>The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or</p>
 <p>The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist.</p>",rheumatoid arthritis,RA,Streamlined,10 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled syringe,9033K,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12442W,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12442W,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12442W,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12442W,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9099X,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,12328W,S,1,5,2,11634,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 units (on a scale of 0-10) in the BASDAI score combined with at least 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must be documented in the patient&apos;s medical notes.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12378L,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed to achieve an adequate response to methotrexate at a dose of at least 20 mg weekly for a minimum period of 3 months; AND</p>
 <p>Patient must have failed to achieve an adequate response to sulfasalazine at a dose of at least 2 g per day for a minimum period of 3 months; or</p>
 <p>Patient must have failed to achieve an adequate response to leflunomide at a dose of up to 20 mg daily for a minimum period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p>Where treatment with methotrexate, sulfasalazine or leflunomide is contraindicated according to the relevant TGA-approved Product Information, details must be provided at the time of application.</p>
 <p>Where intolerance to treatment with methotrexate, sulfasalazine or leflunomide developed during the relevant period of use, which was of a severity to necessitate permanent treatment withdrawal, details of the degree of this toxicity must be provided at the time of application.</p>
 <p align=\""justify\"">The following initiation criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; and</p><p align=\""justify\"">either</p><p align=\""justify\"">(a) an active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p><p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12378L,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12378L,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have had a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12378L,A,1,3,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in in biological medicine of less than 5 years)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with 3 biological medicines for this condition within this treatment cycle; AND</p>
 <p>Patient must not have failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hyrimoz,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug within this treatment cycle, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9104E,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug within this treatment cycle, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Continuing Treatment - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9100Y,A,1,5,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient has either failed or ceased to respond to a PBS-subsidised biological medicine for this condition 5 times, they will not be eligible to receive further PBS-subsidised treatment with a biological medicine for this condition.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have failed to achieve an adequate response following treatment with at least 2 non-steroidal anti-inflammatory drugs (NSAIDs), whilst completing an appropriate exercise program, for a total period of 3 months; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The application must include details of the NSAIDs trialled, their doses and duration of treatment. </p><p align=\""justify\"">If the NSAID dose is less than the maximum recommended dose in the relevant TGA-approved Product Information, the application must include the reason a higher dose cannot be used.</p><p align=\""justify\"">If treatment with NSAIDs is contraindicated according to the relevant TGA-approved Product Information, the application must provide details of the contraindication.</p><p align=\""justify\"">If intolerance to NSAID treatment develops during the relevant period of use which is of a severity to necessitate permanent treatment withdrawal, the application must provide details of the nature and severity of this intolerance. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated at the time of the initial application:</p><p align=\""justify\"">(a) a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale; AND</p><p align=\""justify\"">(b) an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 10 mg per L.</p><p align=\""justify\"">The BASDAI must be determined at the completion of the 3 month NSAID and exercise trial, but prior to ceasing NSAID treatment. The BASDAI must be no more than 1 month old at the time of initial application.</p><p align=\""justify\"">Both ESR and CRP measures should be provided with the initial treatment application and both must be no more than 1 month old. If the above requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reason this criterion cannot be satisfied.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form; and</p><p align=\""justify\"">(iii) a completed Exercise Program Self Certification Form included in the supporting information form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND</p>
 <p>The condition must be radiographically (plain X-ray) confirmed Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; AND</p>
 <p>Patient must have at least 2 of the following: (i) low back pain and stiffness for 3 or more months that is relieved by exercise but not by rest; or (ii) limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by a score of at least 1 on each of the lumbar flexion and lumbar side flexion measurements of the Bath Ankylosing Spondylitis Metrology Index (BASMI); or (iii) limitation of chest expansion relative to normal values for age and gender ; AND</p>
 <p>Patient must have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 4 on a 0-10 scale that is no more than 4 weeks old at the time of application; AND</p>
 <p>Patient must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a C-reactive protein (CRP) level greater than 10 mg per L that is no more than 4 weeks old at the time of application; or</p>
 <p>Patient must have a clinical reason as to why demonstration of an elevated ESR or CRP cannot be met and the application must state the reason; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form which includes the following:</p><p align=\""justify\"">(i) a copy of the radiological report confirming Grade II bilateral sacroiliitis or Grade III unilateral sacroiliitis; and</p><p align=\""justify\"">(ii) a completed BASDAI Assessment Form.</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to an initial course of treatment must be conducted following a minimum of 12 weeks of therapy. An application for the continuing treatment must be accompanied with the assessment of response and submitted to the Department of Human Services no later than 4 weeks from the date of completion of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Idacio,Injection 40 mg in 0.8 mL pre-filled pen,9103D,A,1,3,2,NA,"<p>Ankylosing spondylitis</p>
<p>Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years)</p>
<p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND</p>
 <p>Patient must not have already failed, or ceased to respond to, PBS-subsidised treatment with this drug for this condition during the current treatment cycle; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised biological medicine treatment for this condition who wishes to change or recommence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised biological medicine treatment, within the timeframes specified below.</p>
 <p align=\""justify\"">Where the most recent course of PBS-subsidised biological medicine treatment was approved under either Initial 1, Initial 2, Initial 3 or continuing treatment restrictions, an assessment of a patient&apos;s response must have been conducted following a minimum of 12 weeks of therapy and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled pen,12415K,S,1,5,2,11523,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The measurement of response to the prior course of therapy must have been conducted following a minimum of 12 weeks of therapy with this drug and must be documented in the patient&apos;s medical records.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Streamlined,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>First continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug for this condition under the first continuing treatment restriction to complete 24 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the subsequent continuing Authority Required (in writing) treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restrictions; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Hadlima,Injection 40 mg in 0.8 mL pre-filled pen,9102C,A,1,5,2,NA,"<p>Severe psoriatic arthritis</p>
<p>Subsequent continuing treatment</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of psoriatic arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment per subsequent continuing treatment course authorised under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an erythrocyte sedimentation rate (ESR) no greater than 25 mm per hour or a C-reactive protein (CRP) level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; and</p><p align=\""justify\"">either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following major active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The same indices of disease severity used to establish baseline at the commencement of treatment with each initial treatment application must be used to determine response for all subsequent continuing treatments.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug within this treatment cycle, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition within this treatment cycle. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",psoriatic arthritis,PsA,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>First continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Subsequent continuing treatment</p>
<p>Patient must have received this drug as their most recent course of PBS-subsidised biological medicine treatment for this condition; AND</p>
 <p>Patient must have demonstrated an adequate response to treatment with this drug; AND</p>
 <p>Patient must not receive more than 24 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>

 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(a) a completed authority prescription form; and</p><p align=\""justify\"">(b) a completed Ankylosing Spondylitis PBS Authority Application - Supporting Information Form.</p>
 <p align=\""justify\"">An adequate response is defined as an improvement from baseline of at least 2 of the BASDAI and 1 of the following:</p><p align=\""justify\"">(a) an ESR measurement no greater than 25 mm per hour; or</p><p align=\""justify\"">(b) a CRP measurement no greater than 10 mg per L; or</p><p align=\""justify\"">(c) an ESR or CRP measurement reduced by at least 20% from baseline.</p><p align=\""justify\"">Where only 1 acute phase reactant measurement is supplied in the first application for PBS-subsidised treatment, that same marker must be measured and supplied in all subsequent continuing treatment applications.</p>
 <p align=\""justify\"">All measurements provided must be no more than 1 month old at the time of application.</p>
 <p align=\""justify\"">An application for the continuing treatment must be accompanied with the assessment of response following a minimum of 12 weeks of therapy with this drug and submitted to the Department of Human Services no later than 4 weeks from the date of completion of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment.</p>
 <p align=\""justify\"">Where the response assessment is not submitted within this timeframe, the patient will be deemed to have failed to respond to treatment with this drug.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure.</p>
 <p align=\""justify\"">A patient may re-trial this drug after a minimum of 5 years have elapsed between the date the last prescription for a PBS-subsidised biological medicine was approved in this cycle and the date of the first application under a new cycle under the Initial 3 treatment restriction.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Amgevita,Injection 40 mg in 0.8 mL pre-filled syringe,9078T,A,1,5,2,NA,"<p>Ankylosing spondylitis</p>
<p>Continuing treatment - balance of supply</p>
<p>Patient must have received insufficient therapy with this drug under the Continuing treatment restriction to complete 24 weeks treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 24 weeks treatment available under the above restriction; AND</p>
 <p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of ankylosing spondylitis.</p>",Ankylosing spondylitis,AS,Authority,40 ,FALSE,FALSE,FALSE,Continuing
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12400P,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 2 (change or re-commencement of treatment after a break in biological medicine of less than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">An adequate response to treatment is defined as:</p><p align=\""justify\"">an ESR no greater than 25 mm per hour or a CRP level no greater than 15 mg per L or either marker reduced by at least 20% from baseline; </p><p align=\""justify\"">AND either of the following:</p><p align=\""justify\"">(a) a reduction in the total active (swollen and tender) joint count by at least 50% from baseline, where baseline is at least 20 active joints; or</p><p align=\""justify\"">(b) a reduction in the number of the following active joints, from at least 4, by at least 50%:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth). </p>
 <p align=\""justify\"">An application for a patient who has received PBS-subsidised treatment with this drug and who wishes to re-commence therapy with this drug, must be accompanied by evidence of a response to the patient&apos;s most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below.</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>
 <p align=\""justify\"">A patient who has demonstrated a response to a course of rituximab must have a PBS-subsidised biological therapy treatment-free period of at least 22 weeks, immediately following the second infusion, before swapping to an alternate biological medicine.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12400P,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)  - balance of supply</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) restriction to complete 16 weeks treatment; or</p>
 <p>Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) to complete 16 weeks of treatment; AND</p>
 <p>The treatment must provide no more than the balance of up to 16 weeks treatment available under the above restrictions.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12400P,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 1 (new patient)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with disease modifying anti-rheumatic drugs (DMARDs) which must include at least 3 months continuous treatment with each of at least 2 DMARDs, one of which must be methotrexate at a dose of at least 20 mg weekly and one of which must be: (i) hydroxychloroquine at a dose of at least 200 mg daily; or (ii) leflunomide at a dose of at least 10 mg daily; or (iii) sulfasalazine at a dose of at least 2 g daily ; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 6 months of intensive treatment with DMARDs which, if methotrexate is contraindicated according to the Therapeutic Goods Administration (TGA)-approved Product Information or cannot be tolerated at a 20 mg weekly dose, must include at least 3 months continuous treatment with each of at least 2 of the following DMARDs: (i) hydroxychloroquine at a dose of at least 200 mg daily; and/or (ii) leflunomide at a dose of at least 10 mg daily; and/or (iii) sulfasalazine at a dose of at least 2 g daily; or</p>
 <p>Patient must have failed, in the 24 months immediately prior to the date of the application, to achieve an adequate response to a trial of at least 3 months of continuous treatment with a DMARD where 2 of: (i) hydroxychloroquine, (ii) leflunomide, (iii) sulfasalazine, are either contraindicated according to the relevant TGA-approved Product Information or cannot be tolerated at the doses specified above in addition to having a contraindication or intolerance to methotrexate: the remaining tolerated DMARD must be trialled at a minimum dose as mentioned above; or</p>
 <p>Patient must have a contraindication/severe intolerance to each of: (i) methotrexate, (ii) hydroxychloroquine, (iii) leflunomide, (iv) sulfasalazine; in such cases, provide details for each of the contraindications/severe intolerances claimed in the authority application; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">If methotrexate is contraindicated according to the TGA-approved product information or cannot be tolerated at a 20 mg weekly dose,the application must include details of the contraindication or intolerance including severity to methotrexate. The maximum tolerated dose of methotrexate must be documented in the application, if applicable.</p><p align=\""justify\"">The application must include details of the DMARDs trialled, their doses and duration of treatment, and all relevant contraindications and/or intolerances including severity. </p><p align=\""justify\"">The requirement to trial at least 2 DMARDs for periods of at least 3 months each can be met using single agents sequentially or by using one or more combinations of DMARDs. </p><p align=\""justify\"">If the requirement to trial 6 months of intensive DMARD therapy with at least 2 DMARDs cannot be met because of contraindications and/or intolerances of a severity necessitating permanent treatment withdrawal to all of the DMARDs specified above, details of the contraindication or intolerance including severity and dose for each DMARD must be provided in the authority application. </p>
 <p align=\""justify\"">The following criteria indicate failure to achieve an adequate response and must be demonstrated in all patients at the time of the initial application:</p><p align=\""justify\"">an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour or a C-reactive protein (CRP) level greater than 15 mg per L; AND either</p><p align=\""justify\"">(a) a total active joint count of at least 20 active (swollen and tender) joints; or</p><p align=\""justify\"">(b) at least 4 active joints from the following list of major joints:</p><p align=\""justify\"">(i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or</p><p align=\""justify\"">(ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">The joint count and ESR and/or CRP must be determined at the completion of the 6 month intensive DMARD trial, but prior to ceasing DMARD therapy. All measures must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">An assessment of a patient&apos;s response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
Adalimumab,Humira,Injection 40 mg in 0.4 mL pre-filled syringe,12400P,A,1,3,2,NA,"<p>Severe active rheumatoid arthritis</p>
<p>Initial treatment - Initial 3 (re-commencement of treatment after a break in biological medicine of more than 24 months)</p>
<p>Must be treated by a rheumatologist; or</p>
 <p>Must be treated by a clinical immunologist with expertise in the management of rheumatoid arthritis; AND</p>
 <p>Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND</p>
 <p>Patient must have a break in treatment of 24 months or more from the most recent PBS-subsidised biological medicine for this condition; AND</p>
 <p>Patient must not have failed to respond to previous PBS-subsidised treatment with this drug for this condition; AND</p>
 <p>Patient must not have already failed , or ceased to respond to, PBS-subsidised biological medicine treatment for this condition 5 times; AND</p>
 <p>The condition must have an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or</p>
 <p>The condition must have a C-reactive protein (CRP) level greater than 15 mg per L; AND</p>
 <p>The condition must have either (a) a total active joint count of at least 20 active (swollen and tender) joints; or (b) at least 4 active major joints; AND</p>
 <p>Patient must not receive more than 16 weeks of treatment under this restriction; AND</p>
 <p>Patient must be aged 18 years or older.</p>

 <p align=\""justify\"">Major joints are defined as (i) elbow, wrist, knee and/or ankle (assessed as swollen and tender); and/or (ii) shoulder and/or hip (assessed as pain in passive movement and restriction of passive movement, where pain and limitation of movement are due to active disease and not irreversible damage such as joint destruction or bony overgrowth).</p>
 <p align=\""justify\"">All measures of joint count and ESR and/or CRP must be no more than 4 weeks old at the time of initial application.</p>
 <p align=\""justify\"">If the requirement to demonstrate an elevated ESR or CRP cannot be met, the application must state the reasons why this criterion cannot be satisfied. Treatment with prednisolone dosed at 7.5 mg or higher daily (or equivalent) or a parenteral steroid within the past month (intramuscular or intravenous methylprednisolone or equivalent) is an acceptable reason.</p>
 <p/><p align=\""justify\"">Where the baseline active joint count is based on total active joints (i.e. more than 20 active joints), response will be determined according to the reduction in the total number of active joints. Where the baseline is determined on total number of major joints, the response must be demonstrated on the total number of major joints. If only an ESR or CRP level is provided with the initial application, the same marker will be used to determine response. </p><p/>
 <p align=\""justify\"">The authority application must be made in writing and must include:</p><p align=\""justify\"">(1) a completed authority prescription form; and</p><p align=\""justify\"">(2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice).</p>
 <p align=\""justify\"">To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction.</p>
 <p align=\""justify\"">Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment.</p>
 <p align=\""justify\"">If a patient fails to demonstrate a response to treatment with this drug under this restriction they will not be eligible to receive further PBS-subsidised treatment with this drug for this condition.</p>",Severe active rheumatoid arthritis,RA,Authority,40 ,FALSE,FALSE,FALSE,Initial
